Page last updated: 2024-08-23

paroxetine and Depressive Disorder, Major

paroxetine has been researched along with Depressive Disorder, Major in 436 studies

Research

Studies (436)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	13 (2.98)	18.2507
2000's	245 (56.19)	29.6817
2010's	149 (34.17)	24.3611
2020's	29 (6.65)	2.80

Authors

Authors	Studies
Fang, M; Feng, Y; Liu, S; Mayes, TL; Wang, G; Xiao, L; Zhou, J	1
Aldosary, F; Blier, P; James, JS; Norris, S; Ritchie, JC; Tremblay, P	1
Cipelli, R; Dell'Osso, B; Di Nicola, M; Martinotti, G; Peduto, I; Pugliese, AC; Signorelli, MS; Ventriglio, A	1
Bai, R; Chen, J; He, X; Hui, Z; Li, L; Li, S; Li, Z; Liu, R; Shen, Y; Xie, X; Yao, Z; Zhang, R; Zhang, S; Zhang, X	1
Chen, JM; Dong, ZQ; Guan, X; Hao, YN; Shen, XL; Xie, QL	1
Hatano, M; Ikuta, T; Iwata, N; Kishi, T; Matsuda, Y; Okuya, M; Sakuma, K	1
Ikenouchi, A; Okamoto, N; Yoshimura, R	1
Amada, N; Futamura, T; Hirose, T; Kakumoto, Y; Kikuchi, T; Maeda, K; Suzuki, M	1
Bressolle-Gomeni, F; Fava, M; Gomeni, R	2
Cao, Q; Rao, Y; Yang, R; Zhao, J	1
Clayton, A; Jacobsen, P; Nomikos, G; Zhong, W	1
Appeldoorn, JTY; Mulder, H; Risselada, AJ; Ruhé, EG; Schene, AH; Simoons, M; van Roon, EN; van Schaik, RHN	1
Holper, L	1
Bianchi, L; Del Duca, E; Esposito, M; Fargnoli, MC; Giunta, A; Manfreda, V; Troisi, A	1
Bai, Y; Chen, R; Chen, X; Feng, Y; Gao, C; Gao, Y; Gillespie, A; Ma, X; Pan, X; Wang, G; Wang, X; Xiao, L; Xie, Y; Xu, X; Zhou, J; Zhu, X	1
Doshi-Velez, F; Hughes, M; McCoy, TH; Perlis, RH; Pradier, MF	1
Liao, XM; Si, TM; Su, YA; Wang, Y; Yu, X	1
Arroo, R; Jaddoa, E; Masania, J; Masiero, E; Sgamma, T; Sillence, D; Zetterström, T	1
Kaya, ME; Novak, B; Park, DI; Turck, CW; Yan, Y	1
Furukawa, TA; Imai, H; Noma, H	1
Alexander, R; Carboni, L; Delafont, B; Domenici, E; Ivanchenko, E; Learned, SM; Ratti, E	1
Chen, RS; Galling, B; Wang, G; Xiao, L; Zhou, J	1
Muraosa, H; Noto, K; Otani, K; Suzuki, A	1
Hasch, A; Herzog, DP; Jene, T; Lieb, K; Lutz, B; Müller, MB; Opitz, V; Pascual Cuadrado, D; Sillaber, I; Tiwari, VK; Treccani, G; van der Kooij, MA	1
Dong, Q; Fan, Y; Guo, H; Hu, D; Ju, Y; Li, L; Li, Z; Liao, M; Liu, B; Liu, J; Lu, X; Sun, J; Wang, M; Zhang, L; Zhang, Y	1
Dong, Z; Kuang, W; Shen, X; Tian, L	1
Badcock, PB; Bailey, AP; Cox, GR; Hetrick, SE; McKenzie, JE; Meader, N; Merry, SN; Moller, CI; Sharma, V	1
Asara, JM; Dournes, C; Filiou, MD; Ising, M; Müller, MB; Park, DI; Sillaber, I; Turck, CW; Webhofer, C	1
Chen, WH; Li, N; Li, SX; Lu, L; Shi, L; Song, M; Wang, XY; Wang, YM; Yang, LL	1
Cole, S; Cyr, N; Eyre, H; Forbes, M; Lavretsky, H; Siddarth, P; Yang, H	1
Bartova, L; Dold, M; Kasper, S; Rupprecht, R	1
Burke, AK; Ellis, SP; Gorlyn, M; Grunebaum, MF; Keilp, JG; Mann, JJ; Oquendo, MA	1
Chen, CY; Ho, PS; Huang, CC; Huang, SY; Kuo, SC; Liang, CS; Lu, RB; Shyu, JF; Yeh, YW; Yen, CH	1
Kato, M; Kinoshita, T; Kugawa, F; Nonen, S; Takekita, Y; Takeuchi, N; Wakeno, M	1
Eriksson, E; Hieronymus, F; Lisinski, A; Nilsson, S	2
Binder, EB; Carrillo-Roa, T; Craighead, WE; Dunlop, BW; Harbich, D; Herzog, DP; Holsboer, F; Labermaier, C; Lareau, C; Mayberg, HS; Müller, MB; Nemeroff, CB; Rex-Haffner, M; Santarelli, S; Scharf, SH; Schmidt, MV; Sillaber, I; Uhr, M; Wagner, KV; Weber, P	1
Baune, BT; Olsen, CK; Sluth, LB	1
Gao, KR; Li, HF; Shen, YF; Yu, H; Yu, YM	1
Bockting, CLH; Bos, FM; Bringmann, LF; DeRubeis, RJ; Dimidjian, S; Fried, EI; Hollon, SD	1
Arikan, MK; Metin, B; Tarhan, N	1
Burke, AK; Chaudhury, SR; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Marver, JE; Metts, AV; Oquendo, MA; Parris, MS	1
Chang, CL; Kao, WT; Lung, FW	1
Dong, QL; Guo, H; He, Y; Li, LJ; Li, WH; Li, ZX; Liao, XH; Liu, TB; Lu, XW; Sun, JR; Xia, MR; Zhang, L; Zhang, Y; Zhao, FT	1
Ball, W; Cai, B; DeMuro, C; Morrison, MF; Snyder, E	1
Christensen, MC; McIntyre, RS; Sluth, LB	1
Jha, MK; Rush, AJ; Trivedi, MH	1
Croarkin, PE; Mills, JA; Strawn, JR	1
Aitchison, KJ; Binder, EB; Carrillo-Roa, T; Cattaneo, A; DeModena, A; Henigsberg, N; Kelsoe, JR; Leckband, SG; Liu, JJ; McCarthy, M; Mors, O; Ren, H; Rietschel, M; Shekhtman, T; Wei, YB	1
Cipriani, A; Furukawa, TA; Ikeda, K; Imai, H; Maruo, K; Noma, H; Shinohara, K; Tanaka, S; Yamawaki, S	1
Blake, CS; Hudd, TR; Nguyen, TT; Rimola-Dejesus, Y; Zaiken, K	1
Kato, M; Kinoshita, T; Koshikawa, Y; Nonen, S; Ogata, H; Sunada, N; Takekita, Y; Wakeno, M	1
Alexander, R; Carboni, L; Delafont, B; Domenici, E; Filosi, M; Ivanchenko, E; Learned, SM; McCarthy, DJ; Ratti, E	1
Chen, JQ; Guo, SC; Huang, Y; Li, GL; Lin, RY; Pan, JY; Qu, SS; Wang, CQ; Wong, HK; Zhang, YC; Zhang, ZJ; Zhao, CH	1
Cao, L; Chen, J; Fang, Y; Hong, W; Peng, D; Wu, Z; Yuan, C; Zhang, C	1
Huang, YS; Huang, YX; Lun, WW; Pan, C; Song, L; Zhang, X	1
Berk, M; Dodd, S; Kelin, K; Mancini, M; Schacht, A	1
Chang, LH; Chen, CH; Hsiao, CF; Hsiao, MC; Hsu, YT; Lai, HL; Lin, HL; Lin, KM; Lin, PS; Liu, CY; Liu, SI; Liu, YL; Shen, WW; Tang, HS; Tsou, HH	1
Amleh, I; Bannoura, I; Danoun, OA; Gluck, MA; Herzallah, MM; Moustafa, AA; Myers, CE; Natsheh, JY; Petrides, G; Sehwail, MA; Simon, JR; Tayem, YI	1
Park, YM	1
Preskorn, SH	2
Bauer, N; Burke, AK; Ellis, SP; Grunebaum, MF; Keilp, JG; Mann, JJ; Oquendo, MA; Sudol, K	1
Chen, J; Wang, Y; Wei, Q; Xie, J; Yu, L	1
de Bodinat, C; Lejoyeux, M; Matharan, S	1
Booij, J; Koster, M; Ruhé, HG; Schene, AH; van Herk, M; Veltman, DJ	1
Montgomery, SA; Reines, EH; Sanchez, C	1
Bechon, E; Cappellin, F; Fania, S; Mengozzi, G; Munno, D; Saroldi, M; Sterpone, S; Zullo, G	1
Alberti, S; Chiesa, A; Han, C; Lee, SJ; Lia, L; Pae, CU; Patkar, AA; Serretti, A	1
Chen, GH; Liu, LN; Wang, XC; Xia, Q; Xu, DJ	1
Ishioka, M; Kaneda, A; Kaneko, S; Nakagami, T; Sugawara, N; Tomita, T; Tsuchimine, S; Yasui-Furukori, N	1
Ishioka, M; Kaneda, A; Nakagami, T; Nakamura, K; Sugawara, N; Tomita, T; Yasui-Furukori, N	2
Amsterdam, J; DeRubeis, RJ; Fournier, JC; Hollon, SD; Shelton, RC	1
Diniz, BS; Reynolds, CF	1
Ishioka, M; Kaneda, A; Kaneko, S; Nakagami, T; Nakamura, K; Tomita, T; Tsuchimine, S; Yasui-Furukori, N	1
Chang, YH; Chen, PS; Chen, SH; Chen, SL; Cheng, LY; Chu, CH; Chuang, HY; Lee, IH; Lu, RB; Wang, YS; Yang, YK; Yeh, TL	1
Ball, WA; Hargreaves, RJ; Lines, C; Reines, SA; Snavely, DB; Szegedi, A	1
Bajo, E; Olgiati, P; Serretti, A	1
IsHak, WW; Karamians, R; Peselow, ED; Pizano, D; Tobia, G	1
Blier, P; Chenu, F; El Iskandrani, KS; El Mansari, M; Manta, S; Oosterhof, C; Shim, S	1
Burke, A; Gorlyn, M; Grunebaum, M; Keilp, J; Mann, JJ; Oquendo, M	1
Helmreich, I; Hiemke, C; Kohnen, R; König, J; Szegedi, A; Tadić, A; Wagner, S	1
Azuma, J; Kato, M; Kinoshita, T; Nonen, S; Serretti, A; Takekita, Y; Wakeno, M	1
Atmaca, M; Güngör, BB; Özdel, K; Özen, NE; Taymur, I	1
Dueñas, H; Haro, JM; Hong, J; Moneta, MV; Montgomery, W; Novick, D; Peng, X	1
Douzenis, A; Gournellis, R; Michopoulos, I; Nikolaou, KN; Papageorgiou, C; Papazahos, C	1
Kaneda, A; Kaneko, S; Nakagami, T; Tomita, T; Yasui-Furukori, N	2
Olgiati, P; Serretti, A	1
Barbui, C; Cipriani, A; Furukawa, TA; Hayasaka, Y; Leucht, S; Magni, LR; Ogawa, Y; Purgato, M; Takeshima, N	1
Miskovic, M	1
Assies, J; Koeter, MW; Mocking, RJ; Ruhé, HG; Schene, AH; Vaz, FM; Verburg, HF; Westerink, AM	1
Chang, CC; Chang, HA; Huang, SY; Kao, LC; Kuo, TB; Tzeng, NS; Yeh, TC	1
Chiu, HF; Correll, CU; Feng, L; Feng, Y; Geng, Y; Guo, T; Hu, CQ; Lai, KY; Ungvari, GS; Wang, G; Xiang, YT; Xiao, L	1
Rush, AJ	1
Abi-Jaoude, E; Healy, D; Jureidini, J; Le Noury, J; Nardo, JM; Raven, M; Tufanaru, C	3
Doshi, P	1
Chun, MR; Chung, MW; Kim, DK; Kim, HD; Kim, JR; Lee, SY; Lim, SW; Myung, W; Na, HS; Woo, HI	1
Linden, DE	1
Sasich, LD	1
Bloch, MH; Freemantle, N; Jakubovski, E; Taylor, MJ; Varigonda, AL	1
Barbui, C; Barth, M; Cipriani, A; Klostermann, S; Kriston, L; Linde, K	1
Birkenhager, TK	1
Hatzinger, M; Holsboer-Trachsler, E; Seifritz, E	1
Aoki, A; Iwashita, K; Matsuda, K; Nakashima, H; Nishimura, M; Ogusu, N; Oniki, K; Ono, T; Saruwatari, J; Shimoda, K; Tsuchimine, S; Ueda, M; Yasui-Furukori, N	1
Datka, W; Dudek, D; Gurwitz, D; Kmiotek, K; Obuchowicz, M; Oved, K; Pilc, A; Rzezniczek, S; Shomron, N; Siwek, M	1
Eriksson, E; Hieronymus, F; Nilsson, S	1
Cipriani, A; Coghill, D; Cohen, D; Cuijpers, P; Del Giovane, C; Hazell, P; Hetrick, SE; Leucht, S; Liu, L; Liu, Y; Michael, KD; Pu, J; Qin, B; Ravindran, AV; Whittington, C; Xie, P; Yang, L; Zhang, Y; Zhou, X	1
Black, JL; Elliott, MA; Frye, MA; Nassan, M; Nicholson, WT; Rohrer Vitek, CR	1
Mulder, R; Rucklidge, JJ; Toop, L	1
Amsterdam, JD; DeRubeis, RJ; Hollon, SD; Schalet, BD; Shelton, RC; Tang, TZ	1
Mai, SM; Xiang, YT; Yang, XH; Zhang, YF; Zheng, W; Zhong, HQ	1
Asara, JM; Dournes, C; Filiou, MD; Gassen, NC; Ising, M; Müller, MB; Park, DI; Rein, T; Sillaber, I; Turck, CW; Uhr, M; Webhofer, C	1
Desbordes, M; Gaillon, G; Guillaume, M; Hébant, B; Lefaucheur, R; Maltête, D	1
Gulbins, E; Kornhuber, J; Kramer, M; Lenz, B; Mühle, C; Reichel, M; Rhein, C; Rotter, A	1
Assies, J; Koeter, MWJ; Mocking, RJT; Nap, TS; Ruhé, HG; Schene, AH; Vaz, FM; Westerink, AM	1
Baldwin, D; Briley, M; Moreno, RA	1
Bozina, N; Lovric, M; Mihaljevic Peles, A; Rojnic Kuzman, M; Sagud, M	1
Alexopoulos, GS	1
Hori, H; Ikenouchi-Sugita, A; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R	3
Aubry, JM; Bertschy, G; Bondolfi, G; Eap, CB; Gervasoni, N; Gex-Fabry, M; Oneda, B	1
Kim, YK; Lee, HY	1
Azuma, J; Fukuda, T; Hosoi, Y; Kato, M; Kinoshita, T; Nonen, S; Okugawa, G; Takekita, Y; Wakeno, M; Yamashita, M	1
Ader, H; Beekman, A; de Haan, M; van Marwijk, HW	1
Booij, J; Fransen, EJ; Franssen, EJ; Michel, MC; Reitsma, JB; Ruhé, HG; Schene, AH; v Weert, HC	1
Andersen, HF; Kilts, CD; Schlaepfer, TE; Wade, AG	1
Baas, F; Booij, J; Michel, MC; Moeton, M; Ooteman, W; Ruhé, HG; Schene, AH	1
Benedetti, F; Colombo, C; Marino, E; Pirovano, A; Smeraldi, E	1
Baker, B; Kolluri, S; Krams, M; Landen, JW; Menniti, FS; Preskorn, SH	1
Bartolic, EI; Carfagno, M; Iyengar, M; Lipschitz, A; Lydiard, RB; Pitts, CD; Rapaport, MH; Schaefer, D	1
Guico-Pabia, CJ; Helzner, EC; Nichols, AI; Patroneva, AL; Paul, J; Preskorn, SH	1
Bayindirli, D; Caykoylu, A; Deniz, O; Ekinci, O; Kuloglu, M; Vural, G	1
Dew, MA; Ginsberg, J; Houck, PR; Ma, Y; Mulsant, BH; Pollock, BG; Reynolds, CF; Smith, GS	1
Calabrese, JR; Findling, RL; Lingler, J; McNamara, NK; Rowles, BM	1
Kashima, H; Suzuki, T; Uchida, H; Watanabe, K	1
Andreescu, C; Begley, AE; Lenze, EJ; Mazumdar, S; Mulsant, BH; Reynolds, CF; Wetherell, JL	1
Asarnow, J; Birmaher, B; Brent, DA; Clarke, GN; Debar, LL; Emslie, GJ; Iyengar, S; Keller, MB; Kennard, B; Leonard, H; Mayes, TL; McCracken, JT; Onorato, M; Porta, G; Ritz, L; Ryan, ND; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Zelazny, J	1
Chang, TT; Chen, YC; Lee, SY; Lêng, CH; Lu, RB; Wang, YS; Wu, JY	1
Blier, P; Boucher, N; de Montigny, C; Debonnel, G; Gobbi, G; Hébert, C; Turcotte, JE	1
Colombo, C; De Ronchi, D; Kato, M; Kinoshita, T; Okugawa, G; Rossini, D; Serretti, A; Zanardi, R	1
Spadone, C	1
Barrett, PS; Carpenter, DJ; Davies, JT; Fong, R; Horrigan, JP; Kraus, JE	1
Eipper, F; Lee, L; Malone, K; Mann, JJ; Milak, MS; Olvet, DM; Oquendo, MA; Parsey, RV	1
Bertoletti, E; Chilovi, BV; Conti, M; Padovani, A; Rozzini, L; Trabucchi, M; Zanetti, M	1
Huhtala, H; Illi, A; Kampman, O; Lehtimäki, T; Leinonen, E; Mononen, N; Poutanen, O; Setälä-Soikkeli, E; Viikki, M	1
Hashimoto, K	1
Hori, H; Ikenouchi-Sugita, A; Miyamoto, K; Nakamura, J; Otani, K; Suzuki, A; Ueda, N; Umene-Nakano, W; Yoshimura, R	1
Deng, X; Glubb, DM; Joyce, PR; Kennedy, MA; McHugh, PC	1
Sussman, N	1
Crain, AL; Godlevsky, OV; O'Connor, PJ; Wei, F; Whitebird, RR	1
Brent, DA	2
Amsterdam, JD; DeRubeis, RJ; Fawcett, J; Hollon, SD; Shelton, RC; Stewart, MO; Strunk, DR	1
Castro, WL; Delgado, PL; El Khoury, A; Mathé, AA; Misiaszek, J; Moreno, FA; Palmer, C; Parkinson, D; Wright, R	1
Iwata, N; Kawashima, K; Kinoshita, Y; Kishi, T; Kitajima, T; Naitoh, H; Nakamura, J; Okochi, T; Okumura, T; Ozaki, N; Tsunoka, T; Yamanouchi, Y; Yoshimura, R	1
Amsterdam, J; DeRubeis, RJ; Hollon, SD; Schalet, B; Shelton, R; Tang, TZ	1
Charles, D; Fava, M; Papakostas, GI	1
Jung, YK; Park, YM	1
Del Rio, J; Elizalde, N; García-García, AL; Gendive, N; Ramirez, MJ; Tordera, RM; Totterdell, S; Venzala, E	1
Nibuya, M; Nomura, S; Takahashi, T	1
Kato, M	1
Nierenberg, AA; Schutte, AJ; Simmons, JH; Thase, ME; van Oers, HJ; Vrijland, P	1
Dienel, A; Gastpar, M; Kasper, S; Kieser, M; Möller, HJ; Müller, WE; Volz, HP	1
Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Nierenberg, AA; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C	1
Chapman, A; Gartlehner, G; Strobelberger, M; Thaler, K	1
Hayashi, K; Hori, H; Ikenouchi-Sugita, A; Katsuki, A; Kodama, Y; Miyamoto, K; Nakamura, J; Ueda, N; Umene-Nakano, W; Yoshimura, R	1
Fischer, K; Goetghebeur, E; Vrijens, B; White, IR	1
Bienfait, KL; Dicke, A; Dobkin, RD; Friedman, J; Gara, M; Marin, H; Mark, MH; Menza, M	1
Booij, J; Franssen, EJ; Michel, MC; Reitsma, JB; Ruhé, HG; Schene, A; van Weert, HC	1
Drago, A; Gibiino, S; Serretti, A	1
Deuschle, M; Gilles, M; Hamann, B; Heuser, I; Kopf, D; Lederbogen, F; Paslakis, G; Westphal, S	1
Chauvet-Gélinier, JC	1
Chan, HW; Fang, CK; Hsiao, CF; Hsiao, MC; Hsu, YT; Kuo, HW; Lin, KM; Liu, CY; Liu, SC; Liu, YL; Lu, SC; Shen, WW; Tang, HS; Tian, JN; Tsai, IJ; Tsou, HH; Wu, CS	1
Aoun, J; Gorsane, MA; Krebs, MO; Soufia, M	1
Hida, E; Tango, T	1
Long, B; Yi, ZH; Zhu, LP	1
Cho, HB; Jeong, HS; Jung, JY; Kim, J; Kim, JE; Kim, TS; Lyoo, IK; Shin, E; Yoon, SJ	1
Gurwitz, D; Morag, A; Oron-Karni, V; Pasmanik-Chor, M; Rehavi, M; Stingl, JC	1
Aursnes, I; Gåsemyr, J; Klemp, M; Natvig, B; Tvete, IF	1
Carpenter, DJ; Davies, JT; Fong, R; Kraus, JE; Moore, C; Thase, ME	1
Barbee, JG; Conrad, EJ; Jamhour, NJ; Reimherr, FW; Shelton, RC; Stewart, JW; Thompson, PM; Thompson, TR	1
Amodeo, L; Biancofiore, A; Castelli, L; Cipriani, D; Leombruni, P; Torta, R	1
Kaneko, S; Yasui-Furukori, N	2
Jakovljevi, M; Mihaljevi-Peles, A; Mück-Seler, D; Pivac, N; Sagud, M	1
Appiani, F; Carroll, BT; Muñoz, C; Trecco, J	1
Fujii, A; Inoue, Y; Kaneko, S; Nakagami, T; Sato, Y; Tomita, T; Tsuchimine, S; Yasui-Furukori, N; Yoshizawa, K	1
Fukuo, Y; Inada, T; Iwata, N; Kawashima, K; Kishi, T; Kitajima, T; Kushima, I; Matsunaga, S; Naitoh, H; Nakamura, J; Okochi, T; Ozaki, N; Umene-Nakano, W; Yoshimura, R	1
Kaneda, A; Kaneko, S; Nakagami, T; Sato, Y; Yasui-Furukori, N	1
Calabrese, JR; Cao, L; Chen, J; Cui, X; Fang, Y; Gao, K; Hong, W; Jiang, K; Wang, Y; Wu, Z; Xu, Y; Yi, Z; Yuan, C	1
Abe, T; Hirano, J; Kashima, H; Mimura, M; Nakajima, S; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K; Yagihashi, T	1
Higuchi, T; Hong, JP; Jung, HY; Kamijima, K; Kunitomi, T; Watanabe, Y	1
Booij, J; Michel, MC; Ruhé, HG; Schene, AH; Veltman, DJ	1
Crnobaric, C; Kecojevic-Miljevic, S; Lecic-Tosevski, D; Miljevic, CD	1
Burke, AK; Duan, N; Ellis, SP; Grunebaum, MF; John Mann, J; Oquendo, MA	1
Archer, G; Bellew, K; Bettica, P; Bryson, H; Bye, A; Fernandes, S; Krishnan, KR; Ratti, E; Squassante, L; Trist, D; Zamuner, S	1
Alexander, R; Archer, G; Evoniuk, G; Graff, O; Krishnan, KR; Lavergne, A; Learned, S; Moate, R; Modell, JG; Ratti, E; Roychowdhury, S; Zamuner, S	1
Inoue, Y; Kaneda, A; Kaneko, S; Nakagami, T; Otani, K; Suzuki, A; Yasui-Furukori, N	1
Andrade, C	1
Horikawa, H; Kanba, S; Kato, T; Mizoguchi, Y; Monji, A; Seki, Y	1
Asarnow, JR; Birmaher, B; Brent, DA; Clarke, G; Emslie, GJ; Keller, MB; Porta, G; Ryan, N; Shamseddeen, W; Wagner, KD	1
Gotzlav, Y; Iancu, I; Kertzman, S; Kotler, M; Reznik, I; Vainder, M; Weizman, A	1
Azuma, J; Hasegawa, R; Hiratsuka, K; Ishiwata, K; Kato, M; Kinoshita, T; Kurosawa, T; Kurose, K; Nishikawa, J; Nonen, S; Okugawa, G; Saito, Y; Wakeno, M	1
Boku, S; Fujisawa, D; Honda, M; Inoue, T; Ishikane, T; Ito, K; Kawamura, K; Koyama, T; Matsubara, R; Ono, Y; Sasaki, K; Shinohara, K; Suzuki, T; Tsuchiya, K	1
Gurwitz, D; Morag, A; Oved, K	1
Gurwitz, D; Morag, A; Oron-Karni, V; Oved, K; Pasmanik-Chor, M; Rehavi, M; Shomron, N; Stingl, JC	1
Kaneko, S; Nakagami, T; Sato, Y; Tsuchimine, S; Yasui-Furukori, N	1
Beeské, S; Griebel, G; Stahl, SM	1
D'haenen, H; Hale, A; Lôo, H	1
König, F; Raape, J; Truöl, S; Von Hippel, C	1
Jayaraman, A; Pesce, V; Roose, S; Yeragani, VK	1
Correll, CU; Pleak, RR	1
Jainer, AK; Silveira, R; Singh, R	1
Ferguson, JM; Lydiard, RB; Thase, ME; Wilcox, CS	1
Mallavarapu, M; Pesce, V; Radhakrishna, RK; Roose, S; Yeragani, VK	1
Bogetto, F; De Leo, C; Eva, C; Marchiaro, L; Milani, AM; Musso, R; Ravizza, L; Rocc, P; Zanalda, E	1
Thase, ME; Trivedi, M	1
Croghan, TW; McCombs, JS; Shi, L; Stimmel, GL	1
Barreira, PJ; Cohen, BM; Hennen, J; Henry, ME; Kaufman, MJ; Michelson, D; Renshaw, PF; Schmidt, ME; Stoddard, E; Vukovic, AJ	1
Miller, M	1
Lima, L; Urbina, M	1
Antonijevic, IA; Holsboer, F; Künzel, H; Murck, H; Nickel, T; Schill, J; Sonntag, A; Steiger, A; Zobel, A	1
Artigas, F; Colombo, C; Fazio, F; Galli, L; Gilardi, MC; Gobbo, C; Lucignani, G; Messa, C; Moresco, RM; Rizzo, G; Smeraldi, E; Zanardi, R	1
Ackl, N; Brunnauer, A; Holsboer, F; Ising, M; Murck, H; Nickel, T; Schill, J; Sonntag, A; Steiger, A; Yassouridis, A; Zihl, J; Zobel, AW	1
Colla, M; Deuschle, M; Hamann, B; Heuser, I; Kniest, A; Krumm, B; Lederbogen, F; Meichel, C	1
Baghai, TC; Bondy, B; Minov, C; Möller, HJ; Rupprecht, R; Schüle, C; Schwarz, MJ; Zwanzger, P	1
Deuschle, M; Hellweg, R; Heuser, I; Hörer, E; Lederbogen, F	1
Ramasubbu, R	2
Dew, MA; Houck, P; Mulsant, BH; Reynolds, CF; Szanto, K	1
Agid, O; Lerer, B	1
Arita, S; Morishita, S	2
Varley, CK	1
Cohen, BM; Frederick, Bd; Hennen, J; Henry, ME; Kaufman, MJ; Renshaw, PF; Schmidt, ME; Stoddard, EP; Villafuerte, RA	1
Cansever, A; Gulcat, Z; Ozsahin, A; Uzun, O	1
Amico, JA; Fabian, TJ; Kroboth, PD; Mulsant, BH; Pollock, BG; Reynolds, CF	1
Argyropoulos, SV; Bell, CJ; Hicks, JA; Nash, JR; Nutt, DJ; Rich, AS; Wilson, SJ	1
Keller, MB	1
Wagner, KD	1
Golden, RN	1
Berman, N; Bowden, CL; Brannan, S; Frazer, A; Houston, JP; Katz, MM; Tekell, JL	1
Davies, JT; Dunner, DL; Pitts, CD; Rapaport, MH; Schneider, LS	1
Adeoye, OM; Begley, AE; Ferrell, RE; Kirshner, MA; Mulsant, BH; Pollock, BG; Reynolds, CF; Seligman, K	1
Bieling, P; Garson, C; Goldapple, K; Kennedy, S; Lau, M; Mayberg, H; Segal, Z	1
Kim, CC; Kim, DW; Kim, HJ; Kim, YJ; Lee, C; Lee, CU; Lee, S; Lee, SJ; Min, WS; Pae, CU; Paik, IH; Serretti, A; Won, WY	1
Connor, DF	1
Hwang, JP; Tsai, SJ; Yang, CH	1
Riddle, MA	1
Hayakawa, Y; Sekine, A; Shimizu, T	1
Anand, A; Berman, RM; Charney, DS; Lynch-Colonese, K; Perry, EB; Sanacora, G	1
Goldapple, K; Kennedy, S; Mayberg, HS; McIntosh, AR; Rafi-Tari, S; Segal, Z; Seminowicz, DA	1
Bergan, A; Chopra, MP; Crits-Christoph, P; DeRubeis, RJ; Gallop, R; O'Reardon, JP	1
Grunze, H; Hörn, M; Hummel, B; Normann, C; Walden, J	1
Demitrack, MA; Detke, MJ; Goldstein, DJ; Lu, Y; Mallinckrodt, C; Wiltse, C	1
Aberg-Wistedt, A; Agren, H; Akerblad, AC; Bengtsson, F; Höglund, P; Reis, M	1
Casciano, R; Chen, J; Geissler, EC; Mallick, R; Panish, JM; Trivedi, MH; Wan, GJ	1
Deuschle, M; Gilles, M; Henn, FA; Heuser, I; Kopf, D; Lederbogen, F; Lehnert, H; Luley, CW; Ritter, S; Weber-Hamann, B; Westphal, S	1
Hashioka, S; Monji, A; Yanagimoto, K; Yoshida, I	1
Boeuve, C; Brunelin, J; D'Amato, T; Dalery, J; Lerond, J; Poulet, E; Saoud, M	1
Anand, A; Baldwin, RM; Bozkurt, A; Charney, D; Innis, RB; Khan, S; Kugaya, A; Malison, RT; Sanacora, G; Seibyl, JP; Staley, JK; Van Dyck, CH	1
Colla, N; Deuschle, M; Erb-Bies, M; Hamann, B; Heuser, I; Kniest, A; Niemann, H	1
Berger, M; Fiebich, BL; Grunze, H; Lieb, K; Normann, C; Walden, J	1
Butters, MA; Houck, PR; Lopresti, BJ; Mathis, CA; Mazumdar, S; Meltzer, CC; Moses-Kolko, E; Mulsant, BH; Price, JC; Reynolds, CF; Weissfeld, LA; Ziolko, SK	1
Hollander, SB; Kremer, C; Murphy, GM; Rodrigues, HE; Schatzberg, AF	1
Dahmen, N; Kohnen, R; Müller, MJ; Rujescu, D; Stassen, HH; Szegedi, A; Tadic, A	3
Greist, J; Mallinckrodt, CH; McNamara, RK; Raskin, J; Rayamajhi, JN	1
Cabanac, F; Pezous, N; Sechter, D; Tournoux, A; Vandel, P; Weiller, E	1
Appelhof, BC; Brouwer, JP; Fliers, E; Hoogendijk, WJ; Huyser, J; Schene, AH; Tijssen, JG; van Dyck, R; Wiersinga, WM	1
Bitter, I; Demitrack, MA; Detke, MJ; Mallinckrodt, CH; McNamara, RK; Wiltse, CG	1
Houck, PR; Koru-Sengul, T; Mazumdar, S; Mulsant, BH; Pollock, BG; Reynolds, CF; Tang, G	1
Basinski, J; Begley, A; Dew, MA; Farhi, P; Mulsant, BH; Reynolds, CF; Whyte, EM	1
Högberg, P; Landén, M; Thase, ME	1
Arima, Y; Kubo, C; Ohtani, H; Sawada, Y; Tsujimoto, M	1
Poverennova, IE; Zolotovskaia, IA	1
Butters, M; Dew, MA; Frank, E; Karp, JF; Kupfer, DJ; Miller, M; Mulsant, BH; Pollock, B; Reynolds, CF; Seligman, K; Stack, J; Weiner, D	1
Addington, S; Dichter, GS; Freid, CM; Shelton, RC; Tomarken, AJ	1
Argyropoulos, S; Hale, AS; Willner, P	1
Baccichet, E; Carreira, I; Lima, L; Peña, S; Urbina, M	1
Dew, MA; Houck, PR; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Schlernitzauer, M; Smith, GS; Stack, JA	1
Malik, A; Ravasia, S	1
Entsuah, R; Padmanabhan, SK; Shelton, C; Vinall, PE	1
Brannan, SK; Delgado, PL; Detke, MJ; Mallinckrodt, CH; McNamara, RK; Tran, PV; Wang, F; Watkin, JG	1
Cyranowski, JM; Fagiolini, A; Frank, E; Kupfer, DJ; Scott, J; Shear, MK; Swartz, H	1
Albert, A; De Bruyckere, K; Demyttenaere, K; Dewé, W; Mesters, P; Sangeleer, M	1
Basinski, J; Butters, MA; Dew, MA; Driscoll, HC; Houck, PR; Mazumdar, S; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Schlernitzauer, MA; Stack, JA	1
Aizenstein, HJ; Dew, MA; Gildengers, AG; Greenhouse, J; Houck, PR; Jones, BL; Mulsant, BH; Pollock, BG; Reynolds, CF	1
Chung, JY; Frank, L; Green, BL; Krupnick, J; Miranda, J; Prasad, M; Revicki, DA; Siddique, J	1
Di Loreto, G; Dionisio, P; Kasper, S; Olivieri, L	1
Girardi, P; Kotzalidis, GD; Lazanio, S; Manfredi, G; Ruberto, A; Tatarelli, R	1
Baldwin, D; Bridgman, K; Buis, C	1
Kashima, H; Nomura, K; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K	1
Fava, M; Mallinckrodt, CH; Martinez, JM; Prakash, A; Watkin, JG; Wohlreich, MM	1
Archer, SL; Baker, G; Chrapko, W; Jurasz, P; Lara, N; Le Mellédo, JM; Newman, SC; Radomski, MW	1
Bartolic, EI; Carpenter, DJ; Danoff, TM; Findling, RL; Fong, R; Gaedigk, A; Gomeni, R; Leeder, JS; Nucci, G; Piergies, AA	1
Arias, B; Catalán, R; Fañanás, L; Gastó, C; Lorenzi, C; Serretti, A	1
Baldwin, DS; Lader, M; Montgomery, SA; Nil, R	1
Appelhof, BC; Brouwer, JP; Fliers, E; Hoogendijk, WJ; Huyser, J; Schene, AH; Tijssen, JG; van Dyck, R; Verweij, M; Wiersinga, WM	1
Bosker, FJ; den Boer, JA; Meesters, Y	1
Hensley, PL	1
Abraham, G; Milev, R; Stuart Lawson, J	1
Arora, S; DeBattista, C; Fava, M; Hughes, RJ; Thase, ME	1
Baldwin, DS; Cooper, JA; Hindmarch, I; Huusom, AK	1
Bensasi, S; Butters, MA; Dew, MA; Frank, E; Gildengers, A; Houck, PR; Karp, J; Kupfer, DJ; Lenze, E; Mazumdar, S; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Schlernitzauer, MA; Stack, JA; Szanto, K; Whyte, EM	1
Evans, DL; Goodkin, R; Guo, Y; Lawson, D; Lawson, K; Lewison, B; Manatunga, AK; Musselman, DL; Nemeroff, CB; Penna, S; Porter, M; Somerset, WI	1
Iga, J; Kinouchi, S; Morita, K; Motoki, I; Numata, S; Ohmori, T; Ohta, K; Rokutan, K; Sano, A; Song, H; Tanabe, H; Tayoshi, S; Ueno, S; Yamauchi, K	1
Bagby, RM; Cohen, NL; Fulton, KA; Greene, AL; Kennedy, SH; Rafi-Tari, S	1
Asnis, GM; De La Garza, R	1
Dinan, TG; O'Brien, SM; Scott, LV	1
Detke, MJ; Mallinckrodt, CH; Perahia, DG; Walker, DJ; Wang, F	1
Carpenter, DJ; Emslie, GJ; Fong, R; Krulewicz, S; Kutcher, S; Lipschitz, A; Machin, A; Wagner, KD; Wilkinson, C	1
Appelhof, BC; Brouwer, JP; Fliers, E; Hoogendijk, WJ; Huyser, J; Peeters, RP; Schene, AH; Tijssen, JG; Van Dyck, R; Visser, TJ; Wiersinga, WM	1
Edwards, JL	1
Bajbouj, M; Danker-Hopfe, H	1
Kim, YK; Lee, KM	1
Belmaker, RH; Nemets, B; Shapira, B; Trachtenberg, A	1
Baekdal, T; Boulenger, JP; Florea, I; Huusom, AK; Sarchiapone, M	1
Braun, M; Connemann, BJ; Freudenmann, RW; Schönfeldt-Lecuona, C; Wolf, RC	1
Cookson, J; Desaiah, D; Gilaberte, I; Kajdasz, DK	1
Greenhill, LL; Moreno, C; Roche, AM	1
Nakao, M; Nomura, K; Takeuchi, T; Teramoto, T; Yano, E	1
Chiu, YL; Chu, TS; Chuang, YF; Hwang, TJ	1
Bohrer, M; Colla, M; Deuschle, M; Hagen, T; Heuser, I; Kronenberg, G; Meichel, K	1
Appelhof, BC; Brouwer, JP; Fliers, E; Hoogendijk, WJ; Huyser, J; Koper, JW; Lamberts, SW; Schene, AH; Tijssen, JG; Van Dyck, R; van Rossum, EF; Wiersinga, WM	1
Bensasi, S; Houck, PR; Lenze, EJ; Miller, MD; Mulsant, BH; Reynolds, CF; Stack, JA; Tew, JD; Whyte, EM	1
Bertschy, G; Bondolfi, G; Golaz, J; Rachid, F	1
Deuschle, M; Gilles, M; Heuser, I; Lederbogen, F; Weber-Hamann, B	1
Hokoishi, K; Iga, J; Kinouchi, S; Nakataki, M; Numata, S; Ohmori, T; Sano, A; Song, H; Tanabe, H; Tayoshi-Shibuya, S; Ueno, S; Yamauchi, K	1
Iga, J; Kinouchi, S; Numata, S; Ohmori, T; Song, H; Tayoshi-Shibuya, S; Ueno, S; Yamauchi, K	1
Rybakowski, JK; Łojko, D	1
Hauser, P; Indest, DW; Loftis, JM; Moles, JK; Morasco, BJ; Rifai, MA	1
Thomsen, PH	1
Andreescu, C; Cyranowski, JM; Dombrovski, AY; Houck, PR; Lenze, EJ; Mazumdar, S; Mulsant, BH; Reynolds, CF	1
Colombo, C; De Ronchi, D; Mandelli, L; Rossini, D; Serretti, A; Tarricone, I; Zanardi, R	1
Ballesteros, J; Callado, LF; Gutiérrez, M	1
Book, SW; Randall, CL; Randall, PK; Thomas, SE	1
Asnis, GM; Borisov, AS; Bruno, CJ; Demetrashvili, MF; Evans, DL; Henderson, MA; Miller, AH; Raison, CL; Reinus, JF; Staab, JP; Weinreib, R; Woolwine, BJ; Zajecka, JM	1
Connor, K; Davidson, JR; Vaishnavi, S	1
Amsterdam, JD; DeRubeis, RJ; Gallop, R; Hollon, SD; Leykin, Y; Shelton, RC	1
Colman, SA; Harrison, GA; Hong, JP; Lee, MS; Lee, P; Liu, CY; Raskin, J; Ruschel, S; Shu, L; Wang, CY; Xu, X	1
John, AP; Koloth, R	1
Bahk, WM; Jon, DI; Lee, SY; Min, KJ; Pae, CU; Yoon, BH	1
Magalhães, PV	1
Detke, MJ; Faries, DE; Mallinckrodt, CH; Meyers, AL; Prakash, A	1
Bensasi, S; Dew, MA; Houck, PR; Lenze, EJ; Mulsant, BH; Pollock, BG; Reynolds, CF; Stack, JA; Whyte, EM	1
Chen, YC; Lu, RB; Wu, YS	1
Edwards, JL; Kirk, KK; Midha, CK	1
Bogetto, F; Crespi, C; Maina, G; Rosso, G	1
Hori, H; Mitoma, M; Miyamoto, K; Nakamura, J; Sugita, A; Ueda, N; Umene, W; Yoshimura, R	1
Bilusic, H; Bozina, N; Jakovljevic, M; Peles, AM; Sagud, M	1
Azuma, J; Fukuda, T; Hosoi, Y; Kato, M; Kinoshita, T; Okugawa, G; Takekita, Y; Wakeno, M; Yamashita, M	1
Miyaoka, H; Sawayama, E; Sawayama, T; Takahashi, M	1
Matsumoto, H; Mikami, K	1
Nomura, S; Sato, Y; Shigemura, J; Yoshino, A	1
Benattia, I; Demitrack, M; Entsuah, R; Nemeroff, CB; Sloan, DM; Thase, ME	1
Azuma, J; Fukuda, T; Hosoi, Y; Ikenaga, Y; Kato, M; Kinoshita, T; Mandelli, L; Okugawa, G; Serretti, A; Takekita, Y; Wakeno, M	1
Bozina, N; Mihaljević-Peles, A; Sagud, M	1
Detke, MJ; Ossanna, MJ; Pritchett, YL; Swindle, RW; Thase, ME; Xu, J	1
Detke, MJ; Fava, M; Houston, JP; Mallinckrodt, CH; Prakash, A; Swindle, R	1
Cooke, C; Gardner, D; Kisely, S; Sketris, I; Smith, AJ; Tett, SE	1
Danhof, M; Della Pasqua, O; Gomeni, R; Santen, G	1
Jakovljevic, M; Kramaric, M; Muck-Seler, D; Mustapic, M; Nedic, G; Peles, AM; Pivac, N; Sagud, M	1
Amsterdam, JD; Beck, AT; Bhar, SS; DeRubeis, RJ; Gallop, R; Gelfand, LA; Hollon, SD; Schmid, SP; Shelton, RC	1
Abebe, K; Asarnow, JR; Birmaher, B; Brent, D; Clarke, G; DeBar, L; Emslie, G; Hughes, C; Iyengar, S; Keller, M; Kennard, B; Leonard, H; McCracken, J; Melhem, N; Onorato, M; Porta, G; Ritz, L; Ryan, N; Spirito, A; Strober, M; Suddath, R; Vitiello, B; Wagner, KD; Zelazny, J	1
Azuma, J; Fukuda, T; Hosoi, Y; Kato, M; Kinoshita, T; Okugawa, G; Serretti, A; Takekita, Y; Wakeno, M	1
Ferrell, RF; Kirshner, M; Lotrich, FE; Pollock, BG; Reynolds Iii, CF	1
Berman, RM; Carson, WH; Fava, M; Hennicken, D; Marcus, RN; McQuade, RD; Simon, JS; Thase, ME; Trivedi, MH	1
Cohen, LS; Heath, AC; Howell, HB; Lin, H; Yonkers, KA	1
DeSantis, M; Einarson, A; Einarson, TR; Kennedy, D; Koren, G; Malm, H; Panchaud, A; Paulus, WD; Pistelli, A	1
Aursnes, I; Gjertsen, MK	1
Gomeni, R; Merlo-Pich, E	1
Ito, H; Narabayashi, M; Nishida, T; Onishi, H; Wada, M	1
Guardia-Olmos, J; Gudayol-Ferré, E; Herrera-Abarca, J; Herrera-Guzmán, D; Herrera-Guzmán, I; Lira-Mandujano, J; Montoya-Pérez, K	1
Lundberg, GD	1
Folkerts, HW; Michael, N; Mücke, S; Schonauer, K; Schulze-Mönking, H; Tölle, R	1
Bump, GM; Dew, MA; Geary, M; Houck, PR; Kupfer, DJ; Mazumdar, S; Pollock, BG; Reynolds, CF; Smith, G	1
Aberg-Wistedt, A; Stain-Malmgren, R; Tham, A	1
Ghaemi, SN; Kirkwood, CK	1
Agren, H; Eriksson, E; Fahlén, T; Landén, M	1
Bakish, D; Beauclair, L; Bélanger, MC; Chouinard, G; Manchanda, R; Morris, P; O'Neill, MC; Ravindran, A; Reesal, R; Remick, R; Saxena, B; Vasavan Nair, NP	1
Poirier, MF	1
Alvarez, E; Artigas, F; Figueras, G; Pérez, V; San Martino, O	1
Bagby, RM; Joffe, RT; Kennedy, SH; Levitan, RD; Levitt, AJ	1
Gaebel, W; Janz, A; Klimke, A; Larisch, R; Müller-Gärtner, HW; Vosberg, H	1
Alborzian, S; Baxter, LR; Brody, AL; Fairbanks, LA; Huang, SC; Maidment, K; Phelps, ME; Saxena, S; Silverman, DH; Wu, HM	1
Benedetti, F; Catalano, M; Di Bella, D; Smeraldi, E; Zanardi, R	1
Burrows, G; Hopwood, M; Maguire, K; Morris, P; Norman, T	1
Anisman, H; Griffiths, J; Merali, Z; Ravindran, AV; Zaharia, MD	1
Hostetter, A; Llewellyn, A; McLaughlin, E; Stowe, ZN; Strader, JR	1
Gentilini, G; Lopez-Silva, S; Lucca, A; Soldarini, A	1
Begley, AE; Mamo, DC; Miller, MD; Mulsant, BH; Pollock, BG; Reynolds, CF; Stack, JA; Sweet, RA	1
Begley, A; Mazumdar, S; Mulsant, B; Pollock, BG; Stack, J; Weber, E	1
Hauger, B; Kaschka, WP; König, F; von Hippel, C; Wolfersdorf, M	1
Broft, A; Laruelle, M; Martinez, D	1
Vallée, JP	1
Dew, MA; Hernandez, CR; Houck, PR; Mulsant, B; Pollock, BG; Reynolds, CF; Smith, GS	1
Aberg-Wistedt, A; Agren, H; Akerblad, AC; Bengtsson, F; Ekselius, L	1
Lee, MS; Nam, JW	1
Amico, JA; Marar, IE; Mulsant, BH; Pollock, BG; Towers, AL	1
Dewan, V	1
Evans, K; Kennedy, S; Knott, V; Mahoney, C	2
Barnett, W; Fritzsche, M; Richter, P; Sattler, HD; von Turner, A	1
Bebb, RA; Leung, M; Morrison, J; Remick, RA; Wrixon, KJ	1
Begley, AE; Bump, GM; Dew, MA; Mazumdar, S; Mulsant, BH; Pollock, BG; Reynolds, CF	1
Bauer, M; Jobert, M; Müller-Oerlinghausen, B; Zaninelli, R	1
Cook, IA; Leuchter, AF	1
Moussavian, H	1
Montgomery, SA	1
Aizenstein, H; Butters, MA; Houck, PR; Mulsant, BH; Nebes, RD; Pollock, BG; Reynolds, CF; Zmuda, MD	1
Emslie, GJ; Mayes, TL	1
Baxter, LR; Brody, AL; Fairbanks, LA; Ho, ML; Mandelkern, MA; Saxena, S	1
Perry, CM; Wellington, K	1
Baldwin, DS; Hawley, CJ; Mellors, K	1
Ginovart, N; Goulding, V; Hood, K; Houle, S; Hussey, D; Meyer, JH; Wilson, AA	1
Butters, MA; Dew, MA; Fabian, TJ; Kroboth, PD; Linares, AM; Mulsant, BH; Pollock, BG; Reynolds, CF; Trottini, M; Zmuda, MD	1
Hubrich-Ungureanu, P; Knopf, U; Thome, J	1
Cusin, C; Lattuada, E; Lilli, R; Lorenzi, C; Rossini, D; Serretti, A; Smeraldi, E; Zanardi, R	2
Aberg-Wistedt, A; El Khoury, A; Johnson, L; Stain-Malmgren, R	1
Buitelaar, JK; Lahuis, B; Vorstman, J	1
Alborzian, S; Baxter, LR; Brody, AL; Ho, MK; Ho, ML; Huang, SC; Maidment, KM; Saxena, S; Wu, HM; Zohrabi, N	1
Fava, M; Gonzales, JS; Hoog, SL; Judge, RA; Kopp, JB; Nilsson, ME	1
Deuschle, M; Henning, O; Heuser, I; Kniest, A; Niedermaier, N	1
Bagby, RM; Kennedy, SH; Vanderkooy, JD	1
Brown, EB; Gonzales, JS; Miner, CM; Munir, R	1
Weintrob, A	1
Parsons, M	1

Reviews

44 review(s) available for paroxetine and Depressive Disorder, Major

Article	Year
Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Molecular psychiatry, 2023, Volume: 28, Issue:1 Topics: Adult; Amitriptyline; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Fluvoxamine; Humans; Mirtazapine; Network Meta-Analysis; Paroxetine; Randomized Controlled Trials as Topic; Reboxetine; Sertraline; Venlafaxine Hydrochloride; Vortioxetine	2023
Efficacy and tolerability of antidepressant drugs in treatment of depression in children and adolescents: a network meta-analysis. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences, 2022, Aug-01, Volume: 51, Issue:4 Topics: Adolescent; Amitriptyline; Antidepressive Agents; Child; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Fluoxetine; Humans; Imipramine; Network Meta-Analysis; Paroxetine; Sertraline; Venlafaxine Hydrochloride	2022
Melancholic features (DSM-IV) predict but do not moderate response to antidepressants in major depression: an individual participant data meta-analysis of 1219 patients. European archives of psychiatry and clinical neuroscience, 2021, Volume: 271, Issue:3 Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Randomized Controlled Trials as Topic; Young Adult	2021
New generation antidepressants for depression in children and adolescents: a network meta-analysis. The Cochrane database of systematic reviews, 2021, 05-24, Volume: 5 Topics: Adolescent; Antidepressive Agents; Bias; Child; Citalopram; Depressive Disorder, Major; Desvenlafaxine Succinate; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Mirtazapine; Network Meta-Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicidal Ideation; Venlafaxine Hydrochloride; Vilazodone Hydrochloride; Vortioxetine	2021
Dose Escalation of Antidepressants in Unipolar Depression: A Meta-Analysis of Double-Blind, Randomized Controlled Trials. Psychotherapy and psychosomatics, 2017, Volume: 86, Issue:5 Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome	2017
When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. The American journal of psychiatry, 2018, 12-01, Volume: 175, Issue:12 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Diagnosis, Differential; Female; Humans; Paroxetine; Risk Factors; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome	2018
Exploratory analyses of effect modifiers in the antidepressant treatment of major depression: Individual-participant data meta-analysis of 2803 participants in seven placebo-controlled randomized trials. Journal of affective disorders, 2019, 05-01, Volume: 250 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depression; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Japan; Male; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome; Venlafaxine Hydrochloride	2019
Treatment response for acute depression is not associated with number of previous episodes: lack of evidence for a clinical staging model for major depressive disorder. Journal of affective disorders, 2013, Sep-05, Volume: 150, Issue:2 Topics: Acute Disease; Adult; Antidepressive Agents; Citalopram; Cyclohexanols; Depression; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Humans; Male; Middle Aged; Paroxetine; Recurrence; Thiophenes; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride	2013
Comparative efficacies of fluoxetine and paroxetine in major depression across varying acute-phase treatment periods: a meta-analysis. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2014, Volume: 6, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2014
A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? International clinical psychopharmacology, 2014, Volume: 29, Issue:4 Topics: Allosteric Site; Animals; Antidepressive Agents, Second-Generation; Citalopram; Depression; Depressive Disorder, Major; Drug Interactions; Evidence-Based Medicine; Humans; Models, Biological; Nerve Tissue Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sertraline	2014
Major depressive disorder in older adults: benefits and hazards of prolonged treatment. Drugs & aging, 2014, Volume: 31, Issue:9 Topics: Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Drug Administration Schedule; Health Services for the Aged; Humans; Paroxetine; Risk Assessment	2014
Systematic Review and Meta-Analysis: Dose-Response Relationship of Selective Serotonin Reuptake Inhibitors in Major Depressive Disorder. The American journal of psychiatry, 2016, Feb-01, Volume: 173, Issue:2 Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome	2016
Efficacy of selective serotonin reuptake inhibitors and adverse events: meta-regression and mediation analysis of placebo-controlled trials. The British journal of psychiatry : the journal of mental science, 2016, Volume: 208, Issue:2 Topics: Antidepressive Agents; Citalopram; Depression; Depressive Disorder, Major; Humans; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors	2016
Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. Lancet (London, England), 2016, Aug-27, Volume: 388, Issue:10047 Topics: Adolescent; Amitriptyline; Antidepressive Agents; Bayes Theorem; Child; Citalopram; Clomipramine; Confounding Factors, Epidemiologic; Depressive Disorder, Major; Desipramine; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Evidence-Based Medicine; Fluoxetine; Humans; Imipramine; Mianserin; Mirtazapine; Nortriptyline; Paroxetine; Piperazines; Randomized Controlled Trials as Topic; Research Design; Sertraline; Treatment Outcome; Triazoles; Venlafaxine Hydrochloride	2016
Pharmacokinetic Pharmacogenetic Prescribing Guidelines for Antidepressants: A Template for Psychiatric Precision Medicine. Mayo Clinic proceedings, 2016, Volume: 91, Issue:7 Topics: Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Pharmacogenetics; Practice Guidelines as Topic; Precision Medicine; Prescription Drugs; Venlafaxine Hydrochloride	2016
Wuling Capsule for Major Depressive Disorder: A Meta-analysis of Randomised Controlled Trials. East Asian archives of psychiatry : official journal of the Hong Kong College of Psychiatrists = Dong Ya jing shen ke xue zhi : Xianggang jing shen ke yi xue yuan qi kan, 2016, Volume: 26, Issue:3 Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; China; Depressive Disorder, Major; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Sertraline; Treatment Outcome; Young Adult	2016
Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. Journal of psychiatric practice, 2008, Volume: 14, Issue:6 Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclohexanols; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Desipramine; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Health Status; Humans; Paroxetine; Thiophenes	2008
[Severe forms of depression: the efficacy of escitalopram]. L'Encephale, 2009, Volume: 35, Issue:2 Topics: Antidepressive Agents, Second-Generation; Citalopram; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Follow-Up Studies; Humans; Paroxetine; Personality Inventory; Psychometrics; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride	2009
Venlafaxine XR therapy for major depression and anxiety disorders. The clinical implications that its advantages pose. Postgraduate medicine, 1999, Volume: 106, Issue:6 Suppl Topics: Adult; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety Disorders; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	1999
Are typical starting doses of the selective serotonin reuptake inhibitors sub-optimal? A meta-analysis of randomized, double-blind, placebo-controlled, dose-finding studies in major depressive disorder. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2010, Volume: 11, Issue:2 Pt 2 Topics: Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Fluoxetine; Fluvoxamine; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome	2010
[Possibility of a pharmacogenetic approach for prediction and personalized medication in major depressive disorder treatment]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology, 2010, Volume: 30, Issue:2 Topics: Antidepressive Agents; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Fibroblast Growth Factor 2; Fluvoxamine; Forecasting; Humans; Meta-Analysis as Topic; Paroxetine; Pharmacogenetics; Polymorphism, Genetic; Precision Medicine; Racial Groups; Randomized Controlled Trials as Topic; Receptor, Serotonin, 5-HT2A; Receptors, Adrenergic, alpha-2; Serotonin Plasma Membrane Transport Proteins	2010
Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression. International clinical psychopharmacology, 2010, Volume: 25, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Fluvoxamine; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Patient Dropouts; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Young Adult	2010
Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. International clinical psychopharmacology, 2010, Volume: 25, Issue:4 Topics: Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypericum; Male; Paroxetine; Plant Extracts; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2010
Differences in efficacy and safety of pharmaceutical treatments between men and women: an umbrella review. PloS one, 2010, Jul-30, Volume: 5, Issue:7 Topics: Depressive Disorder, Major; Female; Humans; Male; Paroxetine; Sex Factors; Treatment Outcome	2010
Specificity profile of paroxetine in major depressive disorder: meta-regression of double-blind, randomized clinical trials. Journal of affective disorders, 2011, Volume: 132, Issue:1-2 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Evidence-Based Medicine; Female; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Randomized Controlled Trials as Topic; Regression Analysis; Sex Factors; Treatment Outcome	2011
[SSRIs and pregnancy: a review of the literature]. L'Encephale, 2010, Volume: 36, Issue:6 Topics: Abnormalities, Drug-Induced; Antidepressive Agents; Depressive Disorder, Major; Drug-Related Side Effects and Adverse Reactions; Female; Heart Defects, Congenital; Humans; Infant, Newborn; Infant, Newborn, Diseases; Paroxetine; Pregnancy; Pregnancy Complications; Pregnancy Trimester, Third; Risk Assessment; Selective Serotonin Reuptake Inhibitors	2010
Meta-regression analysis of paroxetine clinical trial data: does reporting scale matter? Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:2 Topics: Depressive Disorder, Major; Humans; Paroxetine; Randomized Controlled Trials as Topic; Surveys and Questionnaires	2011
Meta-analysis of efficacy and treatment-emergent suicidality in adults by psychiatric indication and age subgroup following initiation of paroxetine therapy: a complete set of randomized placebo-controlled trials. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:11 Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Humans; Mental Disorders; Middle Aged; Paroxetine; Placebos; Randomized Controlled Trials as Topic; Suicide; Young Adult	2011
Optimizing treatment outcomes for patients with depression and generalized anxiety disorder. Psychopharmacology bulletin, 2002,Summer, Volume: 36 Suppl 2 Topics: Antidepressive Agents, Tricyclic; Anxiety Disorders; Cyclohexanols; Depressive Disorder, Major; Humans; Paroxetine; Psychotherapy; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride	2002
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry research, 2003, Sep-30, Volume: 120, Issue:2 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Humans; Male; Paroxetine; Piperazines; Polysomnography; Sleep; Sleep Stages; Triazoles	2003
Paroxetine treatment of major depressive disorder. Psychopharmacology bulletin, 2003,Spring, Volume: 37 Suppl 1 Topics: Acute Disease; Antidepressive Agents, Second-Generation; Anxiety; Depressive Disorder, Major; Humans; Long-Term Care; Paroxetine; Treatment Outcome	2003
Efficacy and tolerability of controlled-release paroxetine. Psychopharmacology bulletin, 2003,Spring, Volume: 37 Suppl 1 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Delayed-Action Preparations; Depressive Disorder, Major; Humans; Paroxetine; Patient Compliance	2003
Discontinuation symptoms in depression and anxiety disorders. The international journal of neuropsychopharmacology, 2007, Volume: 10, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Cyclohexanols; Depressive Disorder, Major; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Substance Withdrawal Syndrome; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Withholding Treatment	2007
Treatment of bereavement-related depression and traumatic grief. Journal of affective disorders, 2006, Volume: 92, Issue:1 Topics: Antidepressive Agents, Tricyclic; Bereavement; Depressive Disorder, Major; Humans; Nortriptyline; Paroxetine; Psychotherapy; Selective Serotonin Reuptake Inhibitors; Stress Disorders, Post-Traumatic	2006
Interferon-induced depression in chronic hepatitis C: a review of its prevalence, risk factors, biology, and treatment approaches. Journal of clinical gastroenterology, 2006, Volume: 40, Issue:4 Topics: Anemia; Antiviral Agents; Depressive Disorder, Major; Hepatitis C, Chronic; Humans; Intercellular Adhesion Molecule-1; Interferon alpha-2; Interferon Type I; Interferon-alpha; Nitric Oxide; Paroxetine; Peptide Hydrolases; Polyethylene Glycols; Prevalence; Recombinant Proteins; Ribavirin; Risk Factors; Selective Serotonin Reuptake Inhibitors; Thyroid Diseases	2006
Pharmacotherapy of child and adolescent depression. Child and adolescent psychiatric clinics of North America, 2006, Volume: 15, Issue:4 Topics: Adolescent; Antidepressive Agents; Child; Citalopram; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Sertraline; Social Behavior	2006
An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:2 Topics: Antidepressive Agents, Second-Generation; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Humans; Paroxetine; Randomized Controlled Trials as Topic; Remission Induction; Thiophenes; Treatment Outcome; Withholding Treatment	2007
[Childhood and adolescent depression]. Nihon rinsho. Japanese journal of clinical medicine, 2007, Volume: 65, Issue:9 Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Cognitive Behavioral Therapy; Contraindications; Depressive Disorder, Major; Humans; Japan; Paroxetine; Psychology, Adolescent; Psychology, Child; Randomized Controlled Trials as Topic; Suicide	2007
Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIs. Biological psychiatry, 2008, Feb-15, Volume: 63, Issue:4 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Sertraline; Venlafaxine Hydrochloride	2008
Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorder. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:6 Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Fluoxetine; Humans; Paroxetine; Placebos; Randomized Controlled Trials as Topic; Remission Induction; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome	2007
Common adverse events associated with an SSRI: meta-analysis of early paroxetine data. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:7 Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Depressive Disorder, Major; Drug Labeling; Humans; Middle Aged; Paroxetine; Risk; Selective Serotonin Reuptake Inhibitors	2008
Pindolol augmentation of antidepressant treatment: recent contributions from brain imaging studies. Biological psychiatry, 2000, Oct-15, Volume: 48, Issue:8 Topics: Animals; Brain; Cerebrovascular Circulation; Clinical Trials as Topic; Depressive Disorder, Major; Drug Synergism; Fluoxetine; Humans; Paroxetine; Pindolol; Rats; Selective Serotonin Reuptake Inhibitors; Tomography, Emission-Computed	2000
A meta-analysis of the efficacy and tolerability of paroxetine versus tricyclic antidepressants in the treatment of major depression. International clinical psychopharmacology, 2001, Volume: 16, Issue:3 Topics: Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-Blind Method; Humans; Paroxetine; Personality Inventory; Randomized Controlled Trials as Topic; Treatment Outcome	2001
Venlafaxine extended-release: a review of its use in the management of major depression. CNS drugs, 2001, Volume: 15, Issue:8 Topics: Antidepressive Agents, Second-Generation; Anxiety; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Interactions; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride	2001

Trials

188 trial(s) available for paroxetine and Depressive Disorder, Major

Article	Year
Sini powder with paroxetine ameliorates major depressive disorder by modulating circadian rhythm: A randomized, double-blind, placebo-controlled trial. Journal of pineal research, 2022, Volume: 73, Issue:4 Topics: Antidepressive Agents; Circadian Rhythm; Depressive Disorder, Major; Drugs, Chinese Herbal; Humans; Melatonin; Paroxetine; Powders; Sleep; Tablets	2022
Artificial intelligence approach for the analysis of placebo-controlled clinical trials in major depressive disorders accounting for individual propensity to respond to placebo. Translational psychiatry, 2023, 04-29, Volume: 13, Issue:1 Topics: Artificial Intelligence; Depressive Disorder, Major; Double-Blind Method; Humans; Paroxetine; Treatment Outcome	2023
Paroxetine, but not Vortioxetine, Impairs Sexual Functioning Compared With Placebo in Healthy Adults: A Randomized, Controlled Trial. The journal of sexual medicine, 2019, Volume: 16, Issue:10 Topics: Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Healthy Volunteers; Humans; Male; Paroxetine; Patient Compliance; Self Report; Sexual Behavior; Sexual Dysfunction, Physiological; Surveys and Questionnaires; Vortioxetine; Young Adult	2019
Effectiveness of mirtazapine as add-on to paroxetine Psychological medicine, 2021, Volume: 51, Issue:7 Topics: Adolescent; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; China; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Young Adult	2021
Folate metabolism biomarkers from two randomised placebo-controlled clinical studies with paroxetine and venlafaxine. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2021, Volume: 22, Issue:4 Topics: Biomarkers; Depressive Disorder, Major; Folic Acid; Humans; Paroxetine; Venlafaxine Hydrochloride	2021
Randomized controlled trial of repetitive transcranial magnetic stimulation combined with paroxetine for the treatment of patients with first-episode major depressive disorder. Psychiatry research, 2017, Volume: 254 Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Transcranial Magnetic Stimulation; Treatment Outcome; Young Adult	2017
Comparing the Immune-Genomic Effects of Vilazodone and Paroxetine in Late-Life Depression: A Pilot Study. Pharmacopsychiatry, 2017, Volume: 50, Issue:6 Topics: Aged; Aged, 80 and over; Antidepressive Agents; Cyclic AMP Response Element-Binding Protein; Cytokines; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; Gene Expression Profiling; Gene Expression Regulation; Humans; Male; Outcome Assessment, Health Care; Paroxetine; Patient Compliance; Pilot Projects; Psychiatric Status Rating Scales; Transcription Factor AP-1; Vilazodone Hydrochloride	2017
Suicidal ideation declines with improvement in the subjective symptoms of major depression. Journal of affective disorders, 2018, Volume: 227 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Suicidal Ideation; Treatment Outcome	2018
The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study. Journal of affective disorders, 2018, 03-15, Volume: 229 Topics: Adult; Antidepressive Agents; Cognition; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Nausea; Paroxetine; Piperazines; Sulfides; Treatment Outcome; Vortioxetine; Wechsler Scales	2018
Efficacy and Safety of Agomelatine vs Paroxetine Hydrochloride in Chinese Han Patients with Major Depressive Disorder: A Multicentre, Double-Blind, Noninferiority, Randomized Controlled Trial. Journal of clinical psychopharmacology, 2018, Volume: 38, Issue:3 Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Asian People; China; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Young Adult	2018
Cross-sectional networks of depressive symptoms before and after antidepressant medication treatment. Social psychiatry and psychiatric epidemiology, 2018, Volume: 53, Issue:6 Topics: Adult; Cross-Sectional Studies; Data Interpretation, Statistical; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Models, Theoretical; Outcome Assessment, Health Care; Paroxetine; Selective Serotonin Reuptake Inhibitors	2018
Effects of anxiety on suicidal ideation: exploratory analysis of a paroxetine versus bupropion randomized trial. International clinical psychopharmacology, 2018, Volume: 33, Issue:5 Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Suicidal Ideation; Suicide, Attempted; Treatment Outcome	2018
5-HTT mRNA level as a potential biomarker of treatment response in patients with major depression in a clinical trial. Journal of affective disorders, 2018, 10-01, Volume: 238 Topics: Adult; Alleles; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Genotype; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; RNA, Messenger; Serotonin Plasma Membrane Transport Proteins; Time Factors; Treatment Outcome	2018
A New Single-Item Sleep Quality Scale: Results of Psychometric Evaluation in Patients With Chronic Primary Insomnia and Depression. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine, 2018, 11-15, Volume: 14, Issue:11 Topics: Adult; Aged; Aprepitant; Comorbidity; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Middle Aged; Paroxetine; Psychometrics; Reproducibility of Results; Sleep Initiation and Maintenance Disorders; Surveys and Questionnaires	2018
Biomarkers for response in major depression: comparing paroxetine and venlafaxine from two randomised placebo-controlled clinical studies. Translational psychiatry, 2019, 08-02, Volume: 9, Issue:1 Topics: Adult; Biomarkers; C-Reactive Protein; Depressive Disorder, Major; Female; Humans; Interleukin-10; Interleukin-6; Male; Middle Aged; Paroxetine; Treatment Outcome; Tumor Necrosis Factor-alpha; Venlafaxine Hydrochloride; Young Adult	2019
A 6-week randomized controlled trial with 4-week follow-up of acupuncture combined with paroxetine in patients with major depressive disorder. Journal of psychiatric research, 2013, Volume: 47, Issue:6 Topics: Acupuncture Therapy; Adult; Combined Modality Therapy; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Young Adult	2013
Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study. Journal of affective disorders, 2013, Sep-25, Volume: 150, Issue:3 Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Buspirone; China; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Remission Induction; Risperidone; Treatment Outcome; Venlafaxine Hydrochloride; Young Adult	2013
[Clinical study of combined treatment of remifemin and paroxetine for perimenopausal depression]. Zhonghua yi xue za zhi, 2013, Feb-26, Volume: 93, Issue:8 Topics: Cimicifuga; Depressive Disorder, Major; Female; Humans; Middle Aged; Paroxetine; Perimenopause; Plant Extracts; Treatment Outcome	2013
SSRI versus bupropion effects on symptom clusters in suicidal depression: post hoc analysis of a randomized clinical trial. The Journal of clinical psychiatry, 2013, Volume: 74, Issue:9 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Psychometrics; Selective Serotonin Reuptake Inhibitors; Suicidal Ideation; Suicide, Attempted; Young Adult	2013
How to switch to agomelatine after an unsuccessful try with paroxetine or venlafaxine. CNS spectrums, 2015, Volume: 20, Issue:1 Topics: Acetamides; Adult; Aged; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Drug Substitution; Female; Humans; Male; Middle Aged; Paroxetine; Venlafaxine Hydrochloride	2015
Gains in employment status following antidepressant medication or cognitive therapy for depression. The British journal of psychiatry : the journal of mental science, 2015, Volume: 206, Issue:4 Topics: Antidepressive Agents; Cognitive Behavioral Therapy; Depression; Depressive Disorder, Major; Employment; Follow-Up Studies; Humans; Odds Ratio; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2015
Venlafaxine, paroxetine and milnacipran for major depressive disorder: a pragmatic 24-week study. The Chinese journal of physiology, 2014, Oct-31, Volume: 57, Issue:5 Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Cyclopropanes; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride	2014
Addition of an NK1 receptor antagonist to an SSRI did not enhance the antidepressant effects of SSRI monotherapy: results from a randomized clinical trial in patients with major depressive disorder. Human psychopharmacology, 2014, Volume: 29, Issue:6 Topics: Adult; Antidepressive Agents; Aprepitant; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Morpholines; Neurokinin-1 Receptor Antagonists; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2014
Treatment-related improvement in neuropsychological functioning in suicidal depressed patients: paroxetine vs. bupropion. Psychiatry research, 2015, Feb-28, Volume: 225, Issue:3 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cognition Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Suicidal Ideation; Suicide, Attempted; Treatment Outcome	2015
Hamilton depression rating subscales to predict antidepressant treatment outcome in the early course of treatment. Journal of affective disorders, 2015, Apr-01, Volume: 175 Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Remission Induction; ROC Curve; Time Factors; Treatment Outcome	2015
Genetic variants in combination with early partial improvement as a clinical utility predictor of treatment outcome in major depressive disorder: the result of two pooled RCTs. Translational psychiatry, 2015, Feb-24, Volume: 5 Topics: Age Factors; Antidepressive Agents; Antidepressive Agents, Second-Generation; Cyclopropanes; Depressive Disorder, Major; Female; Fibroblast Growth Factors; Fluvoxamine; Humans; Japan; Male; Middle Aged; Milnacipran; Paroxetine; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1A; Receptors, Adrenergic, alpha-2; Serotonin Plasma Membrane Transport Proteins; Sex Factors; Treatment Outcome	2015
Fatty acid metabolism and its longitudinal relationship with the hypothalamic-pituitary-adrenal axis in major depression: Associations with prospective antidepressant response. Psychoneuroendocrinology, 2015, Volume: 59 Topics: Adult; Case-Control Studies; Cross-Sectional Studies; Depressive Disorder, Major; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Double-Blind Method; Eicosapentaenoic Acid; Fatty Acids; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Lipid Metabolism; Longitudinal Studies; Male; Paroxetine; Pituitary-Adrenal System; Saliva	2015
Heart rate variability in major depressive disorder and after antidepressant treatment with agomelatine and paroxetine: Findings from the Taiwan Study of Depression and Anxiety (TAISDA). Progress in neuro-psychopharmacology & biological psychiatry, 2016, Jan-04, Volume: 64 Topics: Acetamides; Adult; Aged; Antidepressive Agents; Blood Pressure; Cardiovascular Agents; Case-Control Studies; Depressive Disorder, Major; Female; Heart Rate; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Regression Analysis; Rest; Severity of Illness Index; Taiwan; Young Adult	2016
Measurement-Based Care Versus Standard Care for Major Depression: A Randomized Controlled Trial With Blind Raters. The American journal of psychiatry, 2015, Volume: 172, Issue:10 Topics: Adult; Antidepressive Agents; Clinical Decision-Making; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome	2015
Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ (Clinical research ed.), 2015, Sep-16, Volume: 351 Topics: Adolescent; Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Data Interpretation, Statistical; Depressive Disorder, Major; Double-Blind Method; Evidence-Based Medicine; Humans; Imipramine; Paroxetine; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Treatment Outcome	2015
Efficacy of Hypericum extract WS(®) 5570 compared with paroxetine in patients with a moderate major depressive episode - a subgroup analysis. International journal of psychiatry in clinical practice, 2016, Volume: 20, Issue:3 Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Female; Humans; Hypericum; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Plant Extracts; Selective Serotonin Reuptake Inhibitors; Single-Blind Method; Young Adult	2016
Restoring Study 329: Paroxetine neither effective nor safe for adolescents. The Australian and New Zealand journal of psychiatry, 2016, Volume: 50, Issue:9 Topics: Adolescent; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Imipramine; Male; Outcome Assessment, Health Care; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Failure	2016
Specific Pharmacological Effects of Paroxetine Comprise Psychological but Not Somatic Symptoms of Depression. PloS one, 2016, Volume: 11, Issue:7 Topics: Anxiety; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Medically Unexplained Symptoms; Norepinephrine; Paroxetine; Personality; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin; Treatment Outcome	2016
Study 329 continuation phase: Safety and efficacy of paroxetine and imipramine in extended treatment of adolescent major depression. The International journal of risk & safety in medicine, 2016, Sep-17, Volume: 28, Issue:3 Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Imipramine; Male; Paroxetine; Psychiatric Status Rating Scales; Recurrence	2016
Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. Human psychopharmacology, 2008, Volume: 23, Issue:6 Topics: Adult; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Sexual Dysfunctions, Psychological; Surveys and Questionnaires	2008
MDR1 gene polymorphism: therapeutic response to paroxetine among patients with major depression. Progress in neuro-psychopharmacology & biological psychiatry, 2008, Aug-01, Volume: 32, Issue:6 Topics: Adult; Aged; Alleles; Antidepressive Agents, Second-Generation; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Depressive Disorder, Major; False Positive Reactions; Female; Genotype; Haplotypes; Humans; Male; Markov Chains; Middle Aged; Mutation; Paroxetine; Polymorphism, Genetic; Prospective Studies; Psychiatric Status Rating Scales	2008
Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants. Neuropsychobiology, 2008, Volume: 57, Issue:4 Topics: Adult; Antidepressive Agents; Biomarkers; Brain-Derived Neurotrophic Factor; Case-Control Studies; Chi-Square Distribution; Citalopram; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Matched-Pair Analysis; Neuropsychological Tests; Paroxetine; Reference Values; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride	2008
The alpha 2A-adrenergic receptor gene polymorphism modifies antidepressant responses to milnacipran. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:5 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Alleles; Antidepressive Agents; Asian People; Cyclopropanes; Depressive Disorder, Major; Female; Gene Expression Regulation; Humans; Japan; Male; Middle Aged; Milnacipran; Paroxetine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptors, Adrenergic, alpha-2; Time Factors	2008
Primary care management of major depression in patients aged > or =55 years: outcome of a randomised clinical trial. The British journal of general practice : the journal of the Royal College of General Practitioners, 2008, Volume: 58, Issue:555 Topics: Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Family Practice; Female; Geriatric Assessment; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Treatment Outcome	2008
Evidence why paroxetine dose escalation is not effective in major depressive disorder: a randomized controlled trial with assessment of serotonin transporter occupancy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2009, Volume: 34, Issue:4 Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Brain; Cocaine; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Iodine Radioisotopes; Male; Middle Aged; Paroxetine; Serotonin Plasma Membrane Transport Proteins; Tomography, Emission-Computed, Single-Photon; Young Adult	2009
Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). Journal of psychiatric research, 2009, Volume: 43, Issue:5 Topics: Adult; Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Patient Compliance; Predictive Value of Tests; Psychiatric Status Rating Scales; Remission Induction; Thiophenes; Treatment Outcome	2009
An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:6 Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Excitatory Amino Acid Antagonists; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Paroxetine; Piperidines; Psychiatric Status Rating Scales; Receptors, N-Methyl-D-Aspartate; Research Design; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors; Treatment Failure; Young Adult	2008
Low doses of controlled-release paroxetine in the treatment of late-life depression: a randomized, placebo-controlled trial. The Journal of clinical psychiatry, 2009, Volume: 70, Issue:1 Topics: Aged; Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Patient Satisfaction; Personality Inventory; Quality of Life; Substance Withdrawal Syndrome	2009
Cerebral glucose metabolic response to combined total sleep deprivation and antidepressant treatment in geriatric depression: a randomized, placebo-controlled study. Psychiatry research, 2009, Jan-30, Volume: 171, Issue:1 Topics: Aged; Brain; Cognition Disorders; Depressive Disorder, Major; Glucose; Humans; Magnetic Resonance Imaging; Male; Neuropsychological Tests; Paroxetine; Positron-Emission Tomography; Selective Serotonin Reuptake Inhibitors; Sleep Deprivation	2009
A pilot pharmacotherapy trial for depressed youths at high genetic risk for bipolarity. Journal of child and adolescent psychopharmacology, 2008, Volume: 18, Issue:6 Topics: Adolescent; Antidepressive Agents, Second-Generation; Antimanic Agents; Bipolar Disorder; Child; Child of Impaired Parents; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Male; Paroxetine; Pilot Projects; Risk Factors; Valproic Acid	2008
Should adjunctive antipsychotic treatment be continued in remitted patients with depression? Psychiatry and clinical neurosciences, 2009, Volume: 63, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Long-Term Care; Male; Paroxetine; Psychiatric Status Rating Scales; Sulpiride	2009
High worry severity is associated with poorer acute and maintenance efficacy of antidepressants in late-life depression. Depression and anxiety, 2009, Volume: 26, Issue:3 Topics: Aged; Antidepressive Agents; Anxiety Disorders; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Factor Analysis, Statistical; Female; Humans; Male; Panic Disorder; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index	2009
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. The American journal of psychiatry, 2009, Volume: 166, Issue:4 Topics: Adolescent; Antidepressive Agents; Benzodiazepines; Citalopram; Cognitive Behavioral Therapy; Cross-Sectional Studies; Cyclohexanols; Depressive Disorder, Major; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Suicide; Suicide, Attempted; Venlafaxine Hydrochloride	2009
Lower side effects of milnacipran than paroxetine in the treatment of major depression disorder among Han Chinese in Taiwan. The Chinese journal of physiology, 2008, Dec-31, Volume: 51, Issue:6 Topics: Adolescent; Adult; Aged; Asian People; Cyclopropanes; Depressive Disorder, Major; Follow-Up Studies; Humans; Middle Aged; Milnacipran; Molecular Structure; Paroxetine; Taiwan	2008
Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2009, Volume: 19, Issue:7 Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Chromatography, High Pressure Liquid; Compliance; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Electrochemistry; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Psychiatric Status Rating Scales; Severity of Illness Index; Time Factors; Treatment Outcome	2009
Clinical features of patients with treatment-emergent suicidal behavior following initiation of paroxetine therapy. Journal of affective disorders, 2010, Volume: 120, Issue:1-3 Topics: Adolescent; Adult; Anxiety Disorders; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Suicide, Attempted; Surveys and Questionnaires; Young Adult	2010
Rapid response to paroxetine is associated with plasma paroxetine levels at 4 but not 8 weeks of treatment, and is independent of serotonin transporter promoter polymorphism in Japanese depressed patients. Human psychopharmacology, 2009, Volume: 24, Issue:6 Topics: Adult; Aged; Depressive Disorder, Major; Female; Genotype; Humans; Japan; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Time Factors	2009
Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetine. Progress in neuro-psychopharmacology & biological psychiatry, 2009, Nov-13, Volume: 33, Issue:8 Topics: Adult; Aged; Antidepressive Agents; Blood Platelets; Case-Control Studies; Cyclopropanes; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Male; Middle Aged; Milnacipran; Nitric Oxide; Paroxetine; Statistics as Topic; Time Factors	2009
Can pharmacotherapists be too supportive? A process study of active medication and placebo in the treatment of depression. Psychological medicine, 2010, Volume: 40, Issue:8 Topics: Adult; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Major; Female; Follow-Up Studies; Guideline Adherence; Humans; Male; Middle Aged; Paroxetine; Pharmacists; Professional Competence; Professional-Patient Relations	2010
CSF neurochemicals during tryptophan depletion in individuals with remitted depression and healthy controls. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2010, Volume: 20, Issue:1 Topics: Adult; Analysis of Variance; Case-Control Studies; Chromatography, High Pressure Liquid; Circadian Rhythm; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; Electrochemistry; Female; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Indoles; Male; Methoxyhydroxyphenylglycol; Middle Aged; Neurochemistry; Neuropeptide Y; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Tryptophan; Young Adult	2010
Personality change during depression treatment: a placebo-controlled trial. Archives of general psychiatry, 2009, Volume: 66, Issue:12 Topics: Adolescent; Adult; Aged; Cognitive Behavioral Therapy; Depressive Disorder, Major; Extraversion, Psychological; Humans; Neurotic Disorders; Observer Variation; Paroxetine; Personality; Personality Inventory; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome	2009
Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; China; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Remission Induction; Treatment Outcome; Venlafaxine Hydrochloride	2010
No difference in adherence to paroxetine between depressed patients with early remission and those with late remission based on monitoring of plasma paroxetine concentrations. Human psychopharmacology, 2010, Volume: 25, Issue:6 Topics: Adult; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Hospitals, University; Humans; Inpatients; Male; Medication Adherence; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2010
Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2011, Volume: 19, Issue:3 Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Nortriptyline; Parkinson Disease; Paroxetine; Placebos; Psychiatric Status Rating Scales	2011
[Dose-escalation of SSRIS in major depressive disorder. Should not be recommended in current guidelines]. Tijdschrift voor psychiatrie, 2010, Volume: 52, Issue:9 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Paroxetine; Practice Guidelines as Topic; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome	2010
Treatment with paroxetine, but not amitriptyline, lowers levels of lipoprotein(a) in patients with major depression. Journal of psychopharmacology (Oxford, England), 2011, Volume: 25, Issue:10 Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Lipoprotein(a); Male; Middle Aged; Paroxetine	2011
[Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study]. L'Encephale, 2010, Volume: 36, Issue:5 Topics: Adult; Antidepressive Agents, Second-Generation; Anxiety Disorders; Citalopram; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; France; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Psychometrics	2010
CYP1A2 genetic polymorphisms are associated with treatment response to the antidepressant paroxetine. Pharmacogenomics, 2010, Volume: 11, Issue:11 Topics: Adult; Antidepressive Agents, Second-Generation; Cohort Studies; Cytochrome P-450 CYP1A2; Depressive Disorder, Major; Female; Humans; Male; Paroxetine; Polymorphism, Single Nucleotide; Treatment Outcome	2010
[Clinical observation on treatment of major depressive disorder by paroxetine combined with chaihu xiaoyao mixture]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2010, Volume: 30, Issue:12 Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Therapy, Combination; Drugs, Chinese Herbal; Female; Humans; Male; Middle Aged; Paroxetine; Phytotherapy; Young Adult	2010
Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. International journal of clinical practice, 2011, Volume: 65, Issue:3 Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Disorders; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Male; Mianserin; Mirtazapine; Paroxetine; Prospective Studies; Treatment Outcome; Young Adult	2011
A double-blind placebo-controlled trial of lamotrigine as an antidepressant augmentation agent in treatment-refractory unipolar depression. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:10 Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lamotrigine; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Severity of Illness Index; Triazines	2011
Slow versus standard up-titration of paroxetine for the treatment of depression in cancer patients: a pilot study. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2012, Volume: 20, Issue:2 Topics: Adjustment Disorders; Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Drug Administration Schedule; Dysthymic Disorder; Female; Humans; Logistic Models; Male; Middle Aged; Neoplasms; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Quality of Life; Selective Serotonin Reuptake Inhibitors; Time Factors	2012
Baseline lipid levels and acute treatment response to paroxetine and tianeptine in depressed women. Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:3 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cholesterol; Depressive Disorder, Major; Female; Humans; Middle Aged; Paroxetine; Thiazepines; Treatment Outcome; Triglycerides	2011
The influence of personality factors on paroxetine response time in patients with major depression. Journal of affective disorders, 2011, Volume: 135, Issue:1-3 Topics: Adult; Aged; Antidepressive Agents; Character; Depression; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Personality; Personality Disorders; Personality Inventory; Predictive Value of Tests; Selective Serotonin Reuptake Inhibitors; Temperament; Treatment Outcome	2011
A pilot study of the efficacy and safety of paroxetine augmented with risperidone, valproate, buspirone, trazodone, or thyroid hormone in adult Chinese patients with treatment-resistant major depression. Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:5 Topics: Buspirone; China; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Male; Paroxetine; Pilot Projects; Psychiatric Status Rating Scales; Remission Induction; Risperidone; Selective Serotonin Reuptake Inhibitors; Thyroid Hormones; Trazodone; Valproic Acid	2011
Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Progress in neuro-psychopharmacology & biological psychiatry, 2011, Dec-01, Volume: 35, Issue:8 Topics: Adult; Aged; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Drug Substitution; Female; Humans; Male; Middle Aged; Paroxetine; Prospective Studies; Sertraline; Time Factors; Treatment Outcome	2011
Paroxetine controlled-release formulation in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled study in Japan and Korea. Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:7 Topics: Adult; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Japan; Male; Middle Aged; Paroxetine; Republic of Korea; Selective Serotonin Reuptake Inhibitors	2011
Successful pharmacologic treatment of major depressive disorder attenuates amygdala activation to negative facial expressions: a functional magnetic resonance imaging study. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:4 Topics: Adult; Amygdala; Depressive Disorder, Major; Double-Blind Method; Facial Expression; Female; Functional Neuroimaging; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors	2012
Pilot randomized clinical trial of an SSRI vs bupropion: effects on suicidal behavior, ideation, and mood in major depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2012, Volume: 37, Issue:3 Topics: Adolescent; Adult; Affect; Aged; Bupropion; Depressive Disorder, Major; Dopamine Uptake Inhibitors; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Pilot Projects; Selective Serotonin Reuptake Inhibitors; Suicidal Ideation; Suicide; Treatment Outcome	2012
Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. Journal of clinical psychopharmacology, 2011, Volume: 31, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Neurokinin-1 Receptor Antagonists; Paroxetine; Piperazines; Piperidines; Psychiatric Status Rating Scales; Treatment Outcome	2011
Efficacy, safety, and tolerability of a triple reuptake inhibitor GSK372475 in the treatment of patients with major depressive disorder: two randomized, placebo- and active-controlled clinical trials. Journal of psychopharmacology (Oxford, England), 2012, Volume: 26, Issue:5 Topics: Adult; Antidepressive Agents; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Neurotransmitter Uptake Inhibitors; Paroxetine; Placebos; Tropanes; Venlafaxine Hydrochloride	2012
Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. Journal of child and adolescent psychopharmacology, 2012, Volume: 22, Issue:1 Topics: Adolescent; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder, Major; Drug Interactions; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Sleep Wake Disorders; Trazodone; Treatment Outcome; Venlafaxine Hydrochloride	2012
Sertraline treatment of patients with major depressive disorder who failed initial treatment with paroxetine or fluvoxamine. Progress in neuro-psychopharmacology & biological psychiatry, 2012, Aug-07, Volume: 38, Issue:2 Topics: Adult; Aged; Antidepressive Agents; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Drug Administration Schedule; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Sertraline; Severity of Illness Index; Treatment Outcome	2012
Determination of the dose of agomelatine, a melatoninergic agonist and selective 5-HT(2C) antagonist, in the treatment of major depressive disorder: a placebo-controlled dose range study. International clinical psychopharmacology, 2002, Volume: 17, Issue:5 Topics: Acetamides; Adult; Antidepressive Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Melatonin; Paroxetine; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT2C; Receptors, Serotonin; Serotonin Antagonists; Treatment Outcome	2002
Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on long-term heart rate variability measures. Biological psychiatry, 2002, Sep-01, Volume: 52, Issue:5 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Depressive Disorder, Major; Electrocardiography, Ambulatory; Fractals; Heart Rate; Humans; Middle Aged; Myocardial Ischemia; Nortriptyline; Paroxetine; Selective Serotonin Reuptake Inhibitors; Signal Processing, Computer-Assisted; Sleep; Wakefulness	2002
Citalopram treatment of paroxetine-intolerant depressed patients. Depression and anxiety, 2002, Volume: 16, Issue:3 Topics: Adult; Anxiety Disorders; Citalopram; Depressive Disorder, Major; Drug Tolerance; Female; Humans; Male; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index	2002
Major depression with ischemic heart disease: effects of paroxetine and nortriptyline on measures of nonlinearity and chaos of heart rate. Neuropsychobiology, 2002, Volume: 46, Issue:3 Topics: Aged; Analysis of Variance; Antidepressive Agents; Depressive Disorder, Major; Discriminant Analysis; Heart Rate; Humans; Middle Aged; Models, Cardiovascular; Myocardial Ischemia; Nonlinear Dynamics; Nortriptyline; Paroxetine; Psychiatric Status Rating Scales; Time Factors	2002
Decrease of the D4 dopamine receptor messenger RNA expression in lymphocytes from patients with major depression. Progress in neuro-psychopharmacology & biological psychiatry, 2002, Volume: 26, Issue:6 Topics: Actins; Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Biomarkers; Densitometry; Depressive Disorder, Major; Female; Humans; Lymphocytes; Male; Middle Aged; Monocytes; Oligonucleotide Probes; Paroxetine; Psychiatric Status Rating Scales; Receptors, Dopamine D2; Receptors, Dopamine D4; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Selective Serotonin Reuptake Inhibitors	2002
Cerebral blood volume and clinical changes on the third day of placebo substitution for SSRI treatment. Biological psychiatry, 2003, Jan-01, Volume: 53, Issue:1 Topics: Adult; Caudate Nucleus; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Magnetic Resonance Imaging; Male; Paroxetine; Prefrontal Cortex; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires	2003
Clinical and neurobiological effects of tianeptine and paroxetine in major depression. Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:2 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cognition; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Paroxetine; Psychiatric Status Rating Scales; Psychometrics; Task Performance and Analysis; Thiazepines; Treatment Outcome	2003
Antidepressive treatment with amitriptyline and paroxetine: effects on saliva cortisol concentrations. Journal of clinical psychopharmacology, 2003, Volume: 23, Issue:2 Topics: Amitriptyline; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Male; Middle Aged; Paroxetine; Pituitary-Adrenal System; Psychiatric Status Rating Scales; Saliva; Treatment Outcome	2003
Substance P serum levels are increased in major depression: preliminary results. Biological psychiatry, 2003, Mar-15, Volume: 53, Issue:6 Topics: Adult; Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Substance P; Time Factors	2003
Platelet counts in depressed patients treated with amitriptyline or paroxetine. European psychiatry : the journal of the Association of European Psychiatrists, 2003, Volume: 18, Issue:2 Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Platelet Count; Selective Serotonin Reuptake Inhibitors	2003
Occurrence and course of suicidality during short-term treatment of late-life depression. Archives of general psychiatry, 2003, Volume: 60, Issue:6 Topics: Aged; Combined Modality Therapy; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Male; Nortriptyline; Paroxetine; Psychotherapy; Risk Factors; Severity of Illness Index; Suicide; Suicide, Attempted; Time Factors; Treatment Outcome	2003
Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. The international journal of neuropsychopharmacology, 2003, Volume: 6, Issue:1 Topics: Adult; Aged; Algorithms; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Synergism; Female; Fluoxetine; Humans; Male; Middle Aged; Outpatients; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Triiodothyronine	2003
Selective serotonin reuptake inhibitor discontinuation syndrome is associated with a rostral anterior cingulate choline metabolite decrease: a proton magnetic resonance spectroscopic imaging study. Biological psychiatry, 2003, Sep-01, Volume: 54, Issue:5 Topics: Adult; Brain Mapping; Choline; Depressive Disorder, Major; Female; Fluoxetine; Gyrus Cinguli; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Spectroscopy; Paroxetine; Phosphocreatine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Substance Withdrawal Syndrome; Syndrome	2003
Paroxetine-induced hyponatremia in the elderly due to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:3 Topics: Aged; Depressive Disorder, Major; Female; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Osmolar Concentration; Paroxetine; Pilot Projects; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Vasopressins	2003
Correlation of subjective and objective sleep measurements at different stages of the treatment of depression. Psychiatry research, 2003, Sep-30, Volume: 120, Issue:2 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Electroencephalography; Female; Humans; Male; Paroxetine; Piperazines; Polysomnography; Sleep; Sleep Stages; Triazoles	2003
Onset and early behavioral effects of pharmacologically different antidepressants and placebo in depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2004, Volume: 29, Issue:3 Topics: Adult; Affect; Aged; Analysis of Variance; Antidepressive Agents; Chi-Square Distribution; Depressive Disorder, Major; Desipramine; Double-Blind Method; Female; Humans; Logistic Models; Male; Middle Aged; Motor Activity; Paroxetine; Placebo Effect; Time Factors	2004
Efficacy of controlled-release paroxetine in the treatment of late-life depression. The Journal of clinical psychiatry, 2003, Volume: 64, Issue:9 Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors	2003
Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study. Human psychopharmacology, 2004, Volume: 19, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Hematologic Neoplasms; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Treatment Outcome	2004
Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients. International journal of geriatric psychiatry, 2004, Volume: 19, Issue:2 Topics: Aged; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Hospitalization; Humans; Male; Paroxetine; Treatment Outcome; Venlafaxine Hydrochloride	2004
Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:2 Topics: Adrenergic beta-Antagonists; Adult; Aged; Connecticut; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Hospitals, Veterans; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Pindolol; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Veterans	2004
Response to tryptophan depletion in major depression treated with either cognitive therapy or selective serotonin reuptake inhibitor antidepressants. Biological psychiatry, 2004, May-01, Volume: 55, Issue:9 Topics: Cognitive Behavioral Therapy; Cross-Over Studies; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tryptophan	2004
Paroxetine in major depression: correlating plasma concentrations and clinical response. Pharmacopsychiatry, 2004, Volume: 37, Issue:3 Topics: Adult; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Paroxetine; Prospective Studies; Psychiatric Status Rating Scales; Retrospective Studies; ROC Curve; Selective Serotonin Reuptake Inhibitors; Statistics, Nonparametric; Time Factors; Treatment Outcome	2004
Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:4 Topics: Adult; Analysis of Variance; Confidence Intervals; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Logistic Models; Male; Middle Aged; Paroxetine; Sleep Initiation and Maintenance Disorders; Thiophenes	2004
Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Human psychopharmacology, 2004, Volume: 19, Issue:5 Topics: Adolescent; Adult; Aged; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Monitoring; Female; Half-Life; Humans; Male; Middle Aged; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Sex Factors	2004
Repetitive transcranial magnetic stimulation does not potentiate antidepressant treatment. European psychiatry : the journal of the Association of European Psychiatrists, 2004, Volume: 19, Issue:6 Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Humans; Paroxetine; Periodicity; Skull; Surveys and Questionnaires; Transcranial Magnetic Stimulation	2004
Brain serotonin transporter availability predicts treatment response to selective serotonin reuptake inhibitors. Biological psychiatry, 2004, Oct-01, Volume: 56, Issue:7 Topics: Adult; Analysis of Variance; Brain Mapping; Cocaine; Depressive Disorder, Major; Diencephalon; Female; Fluoxetine; Humans; Iodine Radioisotopes; Male; Matched-Pair Analysis; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Radiopharmaceuticals; Reference Values; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	2004
Impaired declarative memory in depressed patients is slow to recover: clinical experience. Pharmacopsychiatry, 2004, Volume: 37, Issue:4 Topics: Amitriptyline; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hydrocortisone; Language Tests; Male; Memory Disorders; Middle Aged; Paroxetine; Recovery of Function; Remission Induction; Saliva; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Verbal Learning	2004
Serum levels of substance P and response to antidepressant pharmacotherapy. Pharmacopsychiatry, 2004, Volume: 37, Issue:5 Topics: Acute Disease; Adult; Antidepressive Agents; Depressive Disorder, Major; Humans; Lamotrigine; Paroxetine; Severity of Illness Index; Substance P; Surveys and Questionnaires; Triazines	2004
Serotonin 1A receptor binding and treatment response in late-life depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2004, Volume: 29, Issue:12 Topics: Aged; Brain; Carbon Isotopes; Case-Control Studies; Depressive Disorder, Major; Drug Interactions; Female; Geriatric Assessment; Humans; Male; Middle Aged; Paroxetine; Piperazines; Positron-Emission Tomography; Protein Binding; Pyridines; Receptor, Serotonin, 5-HT1A; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists	2004
Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Archives of general psychiatry, 2004, Volume: 61, Issue:11 Topics: Adrenergic alpha-Antagonists; Aged; Ambulatory Care; Depressive Disorder, Major; Female; Genetic Markers; Genotype; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mianserin; Mirtazapine; Nerve Tissue Proteins; Paroxetine; Pharmacogenetics; Polymorphism, Genetic; Proportional Hazards Models; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome	2004
Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clinical therapeutics, 2004, Volume: 26, Issue:9 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Europe; Female; Fluoxetine; Humans; Male; Middle Aged; Nausea; Paroxetine; Prevalence; Severity of Illness Index; Sex Factors; Thiophenes; Time Factors; United States	2004
A comparative study of milnacipran and paroxetine in outpatients with major depression. Journal of affective disorders, 2004, Volume: 83, Issue:2-3 Topics: Adrenergic Uptake Inhibitors; Adult; Ambulatory Care; Antidepressive Agents; Cyclopropanes; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Psychomotor Disorders; Reaction Time; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2004
Triiodothyronine addition to paroxetine in the treatment of major depressive disorder. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:12 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Triiodothyronine	2004
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 2004, Volume: 14, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Body Weight; Cardiovascular Diseases; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Electrocardiography; Female; Hemodynamics; Humans; Longitudinal Studies; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Sexual Dysfunction, Physiological; Thiophenes	2004
Estimating treatment effects from longitudinal clinical trial data with missing values: comparative analyses using different methods. Psychiatry research, 2004, Dec-15, Volume: 129, Issue:2 Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cognition Disorders; Data Interpretation, Statistical; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Neuropsychological Tests; Nortriptyline; Paroxetine; Reference Values; Research Design; Severity of Illness Index; Surveys and Questionnaires; Treatment Outcome	2004
Geriatric depression treatment in nonresponders to selective serotonin reuptake inhibitors. The Journal of clinical psychiatry, 2004, Volume: 65, Issue:12 Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Combined Modality Therapy; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Drug Therapy, Combination; Female; Geriatric Assessment; Humans; Lithium; Male; Nortriptyline; Paroxetine; Psychiatric Status Rating Scales; Psychotherapy; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride	2004
Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetine. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:1 Topics: Buspirone; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Incidence; Male; Middle Aged; Norway; Paroxetine; Placebos; Psychiatric Status Rating Scales; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Serotonin Receptor Agonists; Sexual Dysfunctions, Psychological; Surveys and Questionnaires; Sweden	2005
[Clinical effects of paxil in poststroke rehabilitation]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2005, Volume: 105, Issue:1 Topics: Adult; Aged; Brain; Carotid Artery, Internal; Cerebral Infarction; Cluster Analysis; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors	2005
Do venlafaxine XR and paroxetine equally influence negative and positive affect? Journal of affective disorders, 2005, Volume: 85, Issue:3 Topics: Adult; Affect; Antidepressive Agents, Second-Generation; Anxiety Disorders; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Personality Assessment; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride	2005
Dopaminergic mechanism of antidepressant action in depressed patients. Journal of affective disorders, 2005, Volume: 86, Issue:1 Topics: Adult; Affect; Case-Control Studies; Citalopram; Depressive Disorder, Major; Dopamine Antagonists; Female; Fluoxetine; Humans; Male; Middle Aged; Motor Activity; Paroxetine; Receptors, Dopamine D2; Receptors, Dopamine D3; Selective Serotonin Reuptake Inhibitors; Sulpiride; Treatment Outcome	2005
Accelerating symptom-reduction in late-life depression: a double-blind, randomized, placebo-controlled trial of sleep deprivation. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2005, Volume: 13, Issue:5 Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Female; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Sleep Deprivation; Treatment Outcome	2005
Venlafaxine XR demonstrates higher rates of sustained remission compared to fluoxetine, paroxetine or placebo. International clinical psychopharmacology, 2005, Volume: 20, Issue:4 Topics: Antidepressive Agents, Second-Generation; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Placebos; Treatment Outcome; Venlafaxine Hydrochloride	2005
Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. The Journal of clinical psychiatry, 2005, Volume: 66, Issue:6 Topics: Adult; Antidepressive Agents; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Humans; Incidence; Male; Middle Aged; Paroxetine; Placebos; Selective Serotonin Reuptake Inhibitors; Sexual Behavior; Sexual Dysfunctions, Psychological; Thiophenes; Treatment Outcome	2005
Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women. Archives of general psychiatry, 2005, Volume: 62, Issue:8 Topics: Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; Community Mental Health Services; Cost-Benefit Analysis; Depressive Disorder, Major; Drug Costs; Female; Health Care Costs; Health Status; Humans; Minority Groups; Paroxetine; Poverty; Quality of Life; Referral and Consultation; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome	2005
A comparative, randomised, double-blind study of trazodone prolonged-release and paroxetine in the treatment of patients with major depressive disorder. Current medical research and opinion, 2005, Volume: 21, Issue:8 Topics: Adult; Aged; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Trazodone; Treatment Outcome; White People	2005
Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine. Journal of psychopharmacology (Oxford, England), 2006, Volume: 20, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Morpholines; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Sexual Behavior; Sexual Dysfunctions, Psychological	2006
Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder. Journal of clinical psychopharmacology, 2005, Volume: 25, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Paroxetine; Psychological Tests; Sulpiride; Time Factors; Treatment Outcome	2005
Alteration of decreased plasma NO metabolites and platelet NO synthase activity by paroxetine in depressed patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2006, Volume: 31, Issue:6 Topics: Adult; Analysis of Variance; Blood Platelets; Depressive Disorder, Major; Female; Humans; Male; Nitric Oxide; Nitric Oxide Synthase; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors	2006
Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2006, Volume: 31, Issue:6 Topics: Adolescent; Antidepressive Agents, Second-Generation; Area Under Curve; Child; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Obsessive-Compulsive Disorder; Paroxetine; Psychometrics; Time Factors	2006
Glucocorticoids and relapse of major depression (dexamethasone/corticotropin-releasing hormone test in relation to relapse of major depression). Biological psychiatry, 2006, Apr-15, Volume: 59, Issue:8 Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Corticotropin-Releasing Hormone; Depressive Disorder, Major; Dexamethasone; Double-Blind Method; Female; Follow-Up Studies; Glucocorticoids; Humans; Hydrocortisone; Male; Middle Aged; Paroxetine; Pituitary-Adrenal Function Tests; Predictive Value of Tests; Psychiatric Status Rating Scales; Recurrence; Regression Analysis; Time Factors	2006
T3 augmentation of SSRI resistant depression. Journal of affective disorders, 2006, Volume: 91, Issue:2-3 Topics: Adult; Aged; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Drug Resistance; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Triiodothyronine	2006
Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension study. CNS spectrums, 2006, Volume: 11, Issue:2 Topics: Adolescent; Adult; Aged; Benzhydryl Compounds; Central Nervous System Stimulants; Depressive Disorder, Major; Disorders of Excessive Somnolence; Double-Blind Method; Drug Administration Schedule; Drug Synergism; Drug Therapy, Combination; Fatigue; Female; Humans; Male; Middle Aged; Modafinil; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline	2006
A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder. International clinical psychopharmacology, 2006, Volume: 21, Issue:3 Topics: Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Patient Dropouts; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sexual Dysfunction, Physiological; Suicide, Attempted; Tablets; Time Factors; Treatment Outcome; Withholding Treatment	2006
Maintenance treatment of major depression in old age. The New England journal of medicine, 2006, Mar-16, Volume: 354, Issue:11 Topics: Aged; Combined Modality Therapy; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Paroxetine; Psychotherapy; Risk; Secondary Prevention; Selective Serotonin Reuptake Inhibitors	2006
A double-blind, multicenter, parallel-group study of paroxetine, desipramine, or placebo in breast cancer patients (stages I, II, III, and IV) with major depression. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Breast; Breast Neoplasms; Comorbidity; Depressive Disorder, Major; Desipramine; Double-Blind Method; Female; Humans; Middle Aged; Neoplasm Staging; Paroxetine; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome	2006
Gene expression and association analysis of LIM (PDLIM5) in major depression. Neuroscience letters, 2006, Jun-12, Volume: 400, Issue:3 Topics: Adaptor Proteins, Signal Transducing; Adult; Biomarkers; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Gene Expression; Gene Expression Profiling; Humans; Leukocytes; LIM Domain Proteins; Male; Paroxetine; Reproducibility of Results; Risk Assessment; Risk Factors; Sensitivity and Specificity; Statistics as Topic; Treatment Outcome	2006
Sexual function during bupropion or paroxetine treatment of major depressive disorder. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2006, Volume: 51, Issue:4 Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Distribution; Sexual Dysfunction, Physiological	2006
Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. European psychiatry : the journal of the Association of European Psychiatrists, 2006, Volume: 21, Issue:6 Topics: Adult; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Duloxetine Hydrochloride; Female; Humans; Male; Mass Screening; Middle Aged; Paroxetine; Placebo Effect; Prevalence; Remission Induction; Selective Serotonin Reuptake Inhibitors; Thiophenes	2006
Paroxetine treatment in children and adolescents with major depressive disorder: a randomized, multicenter, double-blind, placebo-controlled trial. Journal of the American Academy of Child and Adolescent Psychiatry, 2006, Volume: 45, Issue:6 Topics: Adolescent; Child; Depressive Disorder, Major; Double-Blind Method; Drug Administration Schedule; Female; Humans; Male; Paroxetine; Placebos; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2006
Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression. European journal of endocrinology, 2006, Volume: 154, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Humans; Iodide Peroxidase; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Thyrotropin	2006
The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. International immunopharmacology, 2006, Volume: 6, Issue:8 Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interleukin-12; Male; Middle Aged; Paroxetine; Time Factors; Transforming Growth Factor beta; Transforming Growth Factor beta1; Treatment Outcome; Venlafaxine Hydrochloride	2006
Phenytoin as an augmentation for SSRI failures: a small controlled study. Journal of affective disorders, 2006, Volume: 96, Issue:1-2 Topics: Adult; Aged; Anticonvulsants; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Phenytoin; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2006
A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Current medical research and opinion, 2006, Volume: 22, Issue:7 Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Double-Blind Method; Drug Tolerance; Female; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Safety	2006
Treatment benefits of duloxetine in major depressive disorder as assessed by number needed to treat. International clinical psychopharmacology, 2006, Volume: 21, Issue:5 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Thiophenes; Treatment Outcome	2006
Clinical application of paroxetine for tapering benzodiazepine use in non-major-depressive outpatients visiting an internal medicine clinic. Psychiatry and clinical neurosciences, 2006, Volume: 60, Issue:5 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Benzodiazepines; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Internal Medicine; Male; Middle Aged; Outpatients; Paroxetine; Psychiatric Status Rating Scales; Substance Withdrawal Syndrome	2006
Hippocampal volume reduction and HPA-system activity in major depression. Journal of psychiatric research, 2007, Volume: 41, Issue:7 Topics: Adult; Age Factors; Aged; Amitriptyline; Antidepressive Agents; Cephalometry; Depressive Disorder, Major; Dominance, Cerebral; Female; Follow-Up Studies; Hippocampus; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Image Processing, Computer-Assisted; Length of Stay; Magnetic Resonance Imaging; Male; Middle Aged; Paroxetine; Personality Inventory; Saliva; Statistics as Topic	2007
Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology, 2006, Volume: 31, Issue:10 Topics: Adolescent; Adult; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Hypothalamo-Hypophyseal System; Male; Middle Aged; Paroxetine; Pituitary-Adrenal System; Placebos; Polymorphism, Genetic; Prognosis; Receptors, Glucocorticoid; Selective Serotonin Reuptake Inhibitors	2006
Impact of prior treatment exposure on response to antidepressant treatment in late life. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2006, Volume: 14, Issue:11 Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Combined Modality Therapy; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Lithium Carbonate; Long-Term Care; Male; Nortriptyline; Paroxetine; Psychotherapy; Retreatment; Treatment Failure; Treatment Outcome	2006
The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression. American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics, 2007, Apr-05, Volume: 144B, Issue:3 Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Female; Gene Frequency; Genetic Linkage; Genotype; Humans; Male; Mianserin; Middle Aged; Mirtazapine; Monoamine Oxidase; Paroxetine; Polymorphism, Single Nucleotide; Sex Characteristics; Time Factors; Treatment Outcome	2007
Improved insulin sensitivity in 80 nondiabetic patients with MDD after clinical remission in a double-blind, randomized trial of amitriptyline and paroxetine. The Journal of clinical psychiatry, 2006, Volume: 67, Issue:12 Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Glucose Tolerance Test; Humans; Hydrocortisone; Hypoglycemic Agents; Hypothalamo-Hypophyseal System; Insulin; Insulin Resistance; Male; Middle Aged; Paroxetine; Pituitary-Adrenal System; Risk Factors; Saliva	2006
Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Progress in neuro-psychopharmacology & biological psychiatry, 2007, Apr-13, Volume: 31, Issue:3 Topics: Adult; Antidepressive Agents, Second-Generation; Case-Control Studies; Depressive Disorder, Major; Female; Gene Expression Regulation; Genetic Predisposition to Disease; Humans; Leukocytes; Male; Middle Aged; Paroxetine; RNA, Messenger; Vascular Endothelial Growth Factor A	2007
A randomized trial of paroxetine to prevent interferon-alpha-induced depression in patients with hepatitis C. Journal of affective disorders, 2007, Volume: 103, Issue:1-3 Topics: Adult; Antidepressive Agents, Second-Generation; Antiviral Agents; Depressive Disorder, Major; Drug Therapy, Combination; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Paroxetine; Personality Inventory; Polyethylene Glycols; Recombinant Proteins; Ribavirin; Treatment Outcome; Veterans	2007
Residual symptoms and recurrence during maintenance treatment of late-life depression. Journal of affective disorders, 2007, Volume: 103, Issue:1-3 Topics: Affect; Aged; Antidepressive Agents, Second-Generation; Anxiety Disorders; Combined Modality Therapy; Comorbidity; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Long-Term Care; Male; Motivation; Paroxetine; Personality Inventory; Psychotherapy; Secondary Prevention; Sleep Wake Disorders; Treatment Outcome	2007
Paroxetine reduces social anxiety in individuals with a co-occurring alcohol use disorder. Journal of anxiety disorders, 2008, Volume: 22, Issue:2 Topics: Adult; Alcohol-Related Disorders; Comorbidity; Depressive Disorder, Major; Diagnosis, Dual (Psychiatry); Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Humans; Male; Paroxetine; Phobic Disorders; Placebos; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome	2008
Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary pharmacology & therapeutics, 2007, May-15, Volume: 25, Issue:10 Topics: Adolescent; Adult; Aged; Antiviral Agents; Depressive Disorder, Major; Double-Blind Method; Female; Hepatitis C, Chronic; Humans; Interferon-alpha; Male; Middle Aged; Paroxetine; Ribavirin	2007
Progressive resistance to a selective serotonin reuptake inhibitor but not to cognitive therapy in the treatment of major depression. Journal of consulting and clinical psychology, 2007, Volume: 75, Issue:2 Topics: Adult; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Disease Progression; Drug Resistance; Female; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome	2007
Once-daily duloxetine 60 mg in the treatment of major depressive disorder: multicenter, double-blind, randomized, paroxetine-controlled, non-inferiority trial in China, Korea, Taiwan and Brazil. Psychiatry and clinical neurosciences, 2007, Volume: 61, Issue:3 Topics: Activities of Daily Living; Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Blood Pressure; Brazil; China; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Female; Heart Rate; Humans; Korea; Male; Middle Aged; Pain; Pain Measurement; Paroxetine; Psychiatric Status Rating Scales; Taiwan; Thiophenes; Weight Gain	2007
Effectiveness and tolerability of paroxetine controlled release (CR) in the treatment of major depressive disorder: an open-label, prospective, multi-center trial in Korea. Human psychopharmacology, 2007, Volume: 22, Issue:6 Topics: Antidepressive Agents, Second-Generation; Delayed-Action Preparations; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Korea; Male; Middle Aged; Paroxetine; Prospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2007
Venlafaxine vs. paroxetine in the acute phase of treatment for major depressive disorder among Han Chinese population in Taiwan. Journal of clinical pharmacy and therapeutics, 2007, Volume: 32, Issue:4 Topics: Acute Disease; Adult; Asian People; China; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Paroxetine; Pharmacogenetics; Prospective Studies; Psychiatric Status Rating Scales; Remission Induction; Selective Serotonin Reuptake Inhibitors; Venlafaxine Hydrochloride	2007
A monoamine oxidase B gene variant and short-term antidepressant treatment response. Progress in neuro-psychopharmacology & biological psychiatry, 2007, Oct-01, Volume: 31, Issue:7 Topics: Adult; Alleles; Antidepressive Agents; Data Interpretation, Statistical; Depressive Disorder, Major; DNA; Double-Blind Method; Female; Humans; Introns; Male; Mianserin; Middle Aged; Mirtazapine; Monoamine Oxidase; Paroxetine; Psychiatric Status Rating Scales; Reverse Transcriptase Polymerase Chain Reaction; Selective Serotonin Reuptake Inhibitors	2007
Combined brief dynamic therapy and pharmacotherapy in the treatment of major depressive disorder: a pilot study. Psychotherapy and psychosomatics, 2007, Volume: 76, Issue:5 Topics: Adolescent; Adult; Aged; Citalopram; Combined Modality Therapy; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Male; Middle Aged; Paroxetine; Pilot Projects; Psychotherapy, Brief; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires	2007
Effects of acute paroxetine treatment on the consumption of cigarette smoking and caffeine in depressed patients. Human psychopharmacology, 2007, Volume: 22, Issue:7 Topics: Adult; Aged; Caffeine; Central Nervous System Stimulants; Chromatography, High Pressure Liquid; Cotinine; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Methoxyhydroxyphenylglycol; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Smoking; Tobacco Use Disorder; Treatment Outcome	2007
Differential antidepressant symptom efficacy: placebo-controlled comparisons of duloxetine and SSRIs (fluoxetine, paroxetine, escitalopram). Neuropsychobiology, 2007, Volume: 56, Issue:2-3 Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Thiophenes; Treatment Outcome	2007
Sequence of improvement in depressive symptoms across cognitive therapy and pharmacotherapy. Journal of affective disorders, 2008, Volume: 110, Issue:1-2 Topics: Adult; Cognition Disorders; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Female; Humans; Male; Paroxetine; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome	2008
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA, 2008, Feb-27, Volume: 299, Issue:8 Topics: Adolescent; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Cyclohexanols; Depressive Disorder, Major; Drug Resistance; Female; Fluoxetine; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride	2008
The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study. Journal of clinical psychopharmacology, 2008, Volume: 28, Issue:2 Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents; Aripiprazole; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Fatigue; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Sertraline; Single-Blind Method; Time Factors; Treatment Outcome; Venlafaxine Hydrochloride; Weight Gain; Withholding Treatment	2008
Pharmacologic treatment of postpartum women with new-onset major depressive disorder: a randomized controlled trial with paroxetine. The Journal of clinical psychiatry, 2008, Volume: 69, Issue:4 Topics: Adult; Breast Feeding; Demography; Depression, Postpartum; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires	2008
Electroconvulsive therapy vs. paroxetine in treatment-resistant depression -- a randomized study. Acta psychiatrica Scandinavica, 1997, Volume: 96, Issue:5 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Retreatment; Treatment Failure; Treatment Outcome	1997
Accelerating response in geriatric depression: a pilot study combining sleep deprivation and paroxetine. Depression and anxiety, 1997, Volume: 6, Issue:3 Topics: Aged; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Major; Electroencephalography; Female; Humans; Male; Paroxetine; Pilot Projects; Sleep; Sleep Deprivation; Statistics, Nonparametric; Time Factors	1997
Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. Journal of clinical psychopharmacology, 1999, Volume: 19, Issue:3 Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Buspirone; Citalopram; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunctions, Psychological	1999
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. Journal of affective disorders, 1999, Volume: 54, Issue:1-2 Topics: Adult; Anxiety; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Male; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome	1999
[The concept of resistant depression and therapeutic strategies, particularly, with venlafaxine]. L'Encephale, 1999, Volume: 25 Spec No 2 Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Cyclohexanols; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Humans; Paroxetine; Remission, Spontaneous; Severity of Illness Index; Venlafaxine Hydrochloride	1999
Selective alteration of personality in response to noradrenergic and serotonergic antidepressant medication in depressed sample: evidence of non-specificity. Psychiatry research, 1999, Jun-30, Volume: 86, Issue:3 Topics: Adolescent; Adrenergic Uptake Inhibitors; Aged; Antidepressive Agents; Depressive Disorder, Major; Desipramine; Female; Humans; Male; Paroxetine; Personality; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome	1999
Lymphocyte proliferation among major depressive and dysthymic patients with typical or atypical features. Journal of affective disorders, 2000, Volume: 58, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Cyclohexanols; Depressive Disorder, Major; Dysthymic Disorder; Female; Fluoxetine; Humans; Immune Tolerance; Lymphocyte Activation; Male; Middle Aged; Paroxetine; Personality Inventory; Sertraline; Venlafaxine Hydrochloride	2000
Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: A prospective double-blind study in depressed elderly patients. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2000,Summer, Volume: 8, Issue:3 Topics: Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Male; Nortriptyline; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2000
Weight change in older depressed patients during acute pharmacotherapy with paroxetine and nortriptyline: a double-blind randomized trial. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2000,Summer, Volume: 8, Issue:3 Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Body Weight; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Male; Middle Aged; Nortriptyline; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome; Weight Gain; Weight Loss	2000
[What is the "best" treatment of depression in general practice?]. Presse medicale (Paris, France : 1983), 2000, Oct-28, Volume: 29, Issue:32 Topics: Adolescent; Adult; Aged; Cognitive Behavioral Therapy; Combined Modality Therapy; Depressive Disorder, Major; Family Practice; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Patient Care Team; Personality Inventory; Problem Solving; Treatment Outcome	2000
Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy. Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:6 Topics: Adolescent; Adult; Analysis of Variance; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Logistic Models; Male; Middle Aged; Paroxetine; Personality Disorders; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome	2000
Pre-treatment EEG and it's relationship to depression severity and paroxetine treatment outcome. Pharmacopsychiatry, 2000, Volume: 33, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Male; Middle Aged; Paroxetine; Severity of Illness Index; Theta Rhythm; Treatment Outcome	2000
Neurophysiologic tests during antidepressive treatment - an exploratory study. Pharmacopsychiatry, 2000, Volume: 33, Issue:6 Topics: Adult; Aged; Amitriptyline; Antidepressive Agents, Tricyclic; Autonomic Nervous System; Depressive Disorder, Major; Doxepin; Female; Fluvoxamine; Heart Rate; Humans; Male; Middle Aged; Neural Conduction; Paroxetine; Psychometrics; Reaction Time; Reflex; Selective Serotonin Reuptake Inhibitors	2000
Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depression and anxiety, 2001, Volume: 13, Issue:1 Topics: Adrenergic Uptake Inhibitors; Aged; Depressive Disorder, Major; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Nortriptyline; Paroxetine; Psychiatric Status Rating Scales; Recurrence; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors	2001
Changes in quantitatively assessed tremor during treatment of major depression with lithium augmented by paroxetine or amitriptyline. Journal of clinical psychopharmacology, 2001, Volume: 21, Issue:2 Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Antimanic Agents; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Lithium Chloride; Male; Middle Aged; Paroxetine; Statistics, Nonparametric; Tremor	2001
Dual-task performance in depressed geriatric patients. Psychiatry research, 2001, Jun-01, Volume: 102, Issue:2 Topics: Aged; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Double-Blind Method; Geriatric Assessment; Humans; Nortriptyline; Paroxetine; Remission Induction; Task Performance and Analysis; Visual Perception	2001
A randomized, double-blind controlled comparison of nefazodone and paroxetine in the treatment of depression: safety, tolerability and efficacy in continuation phase treatment. Journal of psychopharmacology (Oxford, England), 2001, Volume: 15, Issue:3 Topics: Adult; Aged; Bipolar Disorder; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Long-Term Care; Male; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Recurrence; Treatment Outcome; Triazoles	2001
Occupancy of serotonin transporters by paroxetine and citalopram during treatment of depression: a [(11)C]DASB PET imaging study. The American journal of psychiatry, 2001, Volume: 158, Issue:11 Topics: Adult; Binding Sites; Biological Transport; Brain; Caudate Nucleus; Chromatography, High Pressure Liquid; Citalopram; Corpus Striatum; Depressive Disorder, Major; Female; Gyrus Cinguli; Humans; Male; Middle Aged; Paroxetine; Prefrontal Cortex; Putamen; Regression Analysis; Selective Serotonin Reuptake Inhibitors; Thalamus; Tomography, Emission-Computed	2001
Endogenous concentrations of DHEA and DHEA-S decrease with remission of depression in older adults. Biological psychiatry, 2001, Nov-15, Volume: 50, Issue:10 Topics: Aged; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Hydrocortisone; Male; Middle Aged; Nortriptyline; Paroxetine; Personality Inventory; Treatment Outcome	2001
Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:2 Topics: Acute Disease; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Paroxetine; Personality Inventory; Sertraline; Sleep Initiation and Maintenance Disorders; Treatment Outcome	2002
Amitriptyline and paroxetine: effects upon peripheral nervous system (PNS). Journal of clinical psychopharmacology, 2002, Volume: 22, Issue:2 Topics: Adult; Aged; Amitriptyline; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Motor Neurons; Neural Conduction; Paroxetine; Peripheral Nerves; Reaction Time; Sensory Receptor Cells	2002
Switching patients from daily citalopram, paroxetine, or sertraline to once-weekly fluoxetine in the maintenance of response for depression. The Journal of clinical psychiatry, 2002, Volume: 63, Issue:3 Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Drug Administration Schedule; Female; Fluoxetine; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Quality of Life; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; United States	2002
Influence of monoamine oxidase A and serotonin receptor 2A polymorphisms in SSRI antidepressant activity. The international journal of neuropsychopharmacology, 2002, Volume: 5, Issue:1 Topics: Adrenergic beta-Antagonists; Antidepressive Agents, Second-Generation; Antimanic Agents; Depressive Disorder; Depressive Disorder, Major; Double-Blind Method; Drug Synergism; Female; Fluvoxamine; Genotype; Humans; Lithium; Male; Middle Aged; Monoamine Oxidase; Paroxetine; Pindolol; Polymorphism, Genetic; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Sex Characteristics	2002

Other Studies

205 other study(ies) available for paroxetine and Depressive Disorder, Major

Article	Year
The network analysis of depressive symptoms before and after two weeks of antidepressant treatment. Journal of affective disorders, 2022, 02-15, Volume: 299 Topics: Antidepressive Agents; Depression; Depressive Disorder, Major; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2022
Differential Potency of Venlafaxine, Paroxetine, and Atomoxetine to Inhibit Serotonin and Norepinephrine Reuptake in Patients With Major Depressive Disorder. The international journal of neuropsychopharmacology, 2022, 04-19, Volume: 25, Issue:4 Topics: Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Cyclohexanols; Depressive Disorder, Major; Humans; Norepinephrine; Norepinephrine Plasma Membrane Transport Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Tyramine; Venlafaxine Hydrochloride	2022
Adherence to, and Persistence of, Antidepressant Therapy in Patients with Major Depressive Disorder: Results from a Population-based Study in Italy. Current neuropharmacology, 2023, Volume: 21, Issue:3 Topics: Adult; Antidepressive Agents; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Escitalopram; Humans; Italy; Paroxetine; Retrospective Studies; Sertraline; Venlafaxine Hydrochloride; Vortioxetine	2023
Plasma levels of interleukin-8 and response to paroxetine in patients with major depressive disorder. Human psychopharmacology, 2022, Volume: 37, Issue:6 Topics: Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Interleukin-8; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2022
Effects of Paroxetine on Plasma Levels of Vascular Endothelial Growth Factor in Patients with Major Depression. Psychiatria Danubina, 2022,Fall, Volume: 34, Issue:3 Topics: Depression; Depressive Disorder, Major; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Vascular Endothelial Growth Factor A	2022
Synergistic anti-depressive effect of combination treatment of Brexpiprazole and selective serotonin reuptake inhibitors on forced swimming test in mice. Neuropsychopharmacology reports, 2023, Volume: 43, Issue:1 Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Escitalopram; Fluoxetine; Mice; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Swimming	2023
A new method for analyzing clinical trials in depression based on individual propensity to respond to placebo estimated using artificial intelligence. Psychiatry research, 2023, Volume: 327 Topics: Artificial Intelligence; Depression; Depressive Disorder, Major; Humans; Paroxetine; Randomized Controlled Trials as Topic	2023
Modification of the association between paroxetine serum concentration and SERT-occupancy by ABCB1 (P-glycoprotein) polymorphisms in major depressive disorder. Psychiatric genetics, 2020, Volume: 30, Issue:1 Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biomarkers, Pharmacological; Depression; Depressive Disorder, Major; Female; Genotype; Humans; Male; Middle Aged; Paroxetine; Pharmacogenetics; Polymorphism, Single Nucleotide; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins	2020
Combining threshold analysis and GRADE to assess sensitivity to bias in antidepressant treatment recommendations adjusted for depression severity. Research synthesis methods, 2020, Volume: 11, Issue:2 Topics: Acetamides; Adult; Amitriptyline; Antidepressive Agents; Bayes Theorem; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Humans; Network Meta-Analysis; Paroxetine; Publication Bias; Reproducibility of Results; Severity of Illness Index; Treatment Outcome; Venlafaxine Hydrochloride	2020
Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series. Postgraduate medicine, 2020, Volume: 132, Issue:2 Topics: Adult; Agoraphobia; Antibodies, Monoclonal, Humanized; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Depressive Disorder; Depressive Disorder, Major; Female; Humans; Lithium Carbonate; Male; Mental Disorders; Middle Aged; Nordazepam; Panic Disorder; Paroxetine; Psoriasis; Quetiapine Fumarate; Severity of Illness Index; Treatment Outcome; Valproic Acid	2020
Predicting treatment dropout after antidepressant initiation. Translational psychiatry, 2020, 02-06, Volume: 10, Issue:1 Topics: Antidepressive Agents; Depressive Disorder, Major; Humans; Longitudinal Studies; Paroxetine; Retrospective Studies	2020
Antidepressant treatment strategy with an early onset of action improves the clinical outcome in patients with major depressive disorder and high anxiety: a multicenter and 6-week follow-up study. Chinese medical journal, 2020, Mar-20, Issue:6 Topics: Antidepressive Agents; Anxiety; Citalopram; Depressive Disorder, Major; Fluoxetine; Fluvoxamine; Follow-Up Studies; Humans; Least-Squares Analysis; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome	2020
Effect of antidepressant drugs on the brain sphingolipid system. Journal of psychopharmacology (Oxford, England), 2020, Volume: 34, Issue:7 Topics: Acid Ceramidase; Adrenergic Uptake Inhibitors; Animals; Brain; Depressive Disorder, Major; Desipramine; Disease Models, Animal; Male; Mice; Paroxetine; Rats; Rats, Sprague-Dawley; RAW 264.7 Cells; Selective Serotonin Reuptake Inhibitors; Sphingolipids; Sphingomyelin Phosphodiesterase	2020
Paroxetine binding and activation of phosphofructokinase implicates energy metabolism in antidepressant mode of action. Journal of psychiatric research, 2020, Volume: 129 Topics: Antidepressive Agents; Depressive Disorder, Major; Energy Metabolism; Humans; Paroxetine; Phosphofructokinases; Selective Serotonin Reuptake Inhibitors	2020
The association of body mass index (BMI) with treatment outcomes in patients with major depressive disorder. Journal of affective disorders, 2021, 02-15, Volume: 281 Topics: Adult; Antidepressive Agents; Body Mass Index; Depressive Disorder, Major; Humans; Paroxetine; Treatment Outcome	2021
Musical Hallucinations Induced by Conventional Doses of Paroxetine. The American journal of case reports, 2020, Dec-25, Volume: 21 Topics: Adult; Depressive Disorder, Major; Female; Hallucinations; Humans; Music; Paroxetine; Selective Serotonin Reuptake Inhibitors; Young Adult	2020
A distinct transcriptional signature of antidepressant response in hippocampal dentate gyrus granule cells. Translational psychiatry, 2021, 01-05, Volume: 11, Issue:1 Topics: Animals; Antidepressive Agents; Dentate Gyrus; Depressive Disorder, Major; Hippocampus; Mice; Paroxetine	2021
The neuroprogressive nature of major depressive disorder: evidence from an intrinsic connectome analysis. Translational psychiatry, 2021, 02-04, Volume: 11, Issue:1 Topics: Brain; Brain Mapping; Connectome; Depressive Disorder, Major; Executive Function; Humans; Magnetic Resonance Imaging; Paroxetine	2021
Plasma levels of interleukin-6 and antidepressant response to Paroxetine in Chinese depressive patients. Psychiatry research, 2021, Volume: 297 Topics: Antidepressive Agents; China; Depressive Disorder, Major; Female; Humans; Interleukin-6; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2021
Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin-proteasome systems. Translational psychiatry, 2017, 04-04, Volume: 7, Issue:4 Topics: Animals; Antidepressive Agents; Depressive Disorder, Major; Glutamic Acid; Hippocampus; Humans; Leukocytes, Mononuclear; Male; Metabolomics; Mice; Mice, Inbred DBA; Nitric Oxide Synthase Type I; Paroxetine; Proteasome Endopeptidase Complex; Proteomics; Receptors, N-Methyl-D-Aspartate; Swimming; Ubiquitin	2017
Differences in immunomodulatory properties between venlafaxine and paroxetine in patients with major depressive disorder. Psychoneuroendocrinology, 2018, Volume: 87 Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Case-Control Studies; China; Cytokines; Depression; Depressive Disorder, Major; Female; Humans; Interleukin-1beta; Interleukin-6; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Treatment Outcome; Venlafaxine Hydrochloride	2018
Therapeutic Response to Paroxetine in Major Depressive Disorder Predicted by DNA Methylation. Neuropsychobiology, 2017, Volume: 75, Issue:2 Topics: Adaptor Proteins, Signal Transducing; Adult; Aged; Cluster Analysis; CpG Islands; Depressive Disorder, Major; DNA Methylation; Female; Humans; Male; Middle Aged; Oligonucleotide Array Sequence Analysis; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sulfotransferases	2017
Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: a mega-analysis of citalopram and paroxetine in adult depression. Molecular psychiatry, 2018, Volume: 23, Issue:8 Topics: Citalopram; Depressive Disorder, Major; Humans; Paroxetine; Placebo Effect; Randomized Controlled Trials as Topic; Research Design; Selective Serotonin Reuptake Inhibitors	2018
Common genes associated with antidepressant response in mouse and man identify key role of glucocorticoid receptor sensitivity. PLoS biology, 2017, Volume: 15, Issue:12 Topics: Animals; Antidepressive Agents; Biomarkers, Pharmacological; Brain; Corticosterone; Depressive Disorder, Major; Gene Expression Profiling; Gene Expression Regulation; Humans; Mice; Mice, Inbred DBA; Multigene Family; Paroxetine; Receptors, Glucocorticoid	2017
EEG gamma synchronization is associated with response to paroxetine treatment. Journal of affective disorders, 2018, 08-01, Volume: 235 Topics: Adult; Antidepressive Agents, Second-Generation; Brain; Depressive Disorder, Major; Electroencephalography; Female; Gamma Rhythm; Humans; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Rest; Retrospective Studies; Treatment Outcome	2018
A shared effect of paroxetine treatment on gray matter volume in depressive patients with and without childhood maltreatment: A voxel-based morphometry study. CNS neuroscience & therapeutics, 2018, Volume: 24, Issue:11 Topics: Adult; Antidepressive Agents, Second-Generation; Child; Child Abuse; Depressive Disorder, Major; Female; Gray Matter; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Paroxetine; Psychiatric Status Rating Scales; Treatment Outcome	2018
Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings. Journal of affective disorders, 2019, 02-15, Volume: 245 Topics: Activities of Daily Living; Adult; Aged; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Middle Aged; Paroxetine; Psychometrics; Randomized Controlled Trials as Topic; Surveys and Questionnaires; Vortioxetine	2019
Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy. Journal of child and adolescent psychopharmacology, 2019, Volume: 29, Issue:4 Topics: Adolescent; Citalopram; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Fluoxetine; Humans; Monte Carlo Method; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2019
A functional variant in the serotonin receptor 7 gene (HTR7), rs7905446, is associated with good response to SSRIs in bipolar and unipolar depression. Molecular psychiatry, 2020, Volume: 25, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Animals; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Receptors, Serotonin; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sertraline; Young Adult	2020
A Case Report of Serotonin Syndrome in a Patient on Selective Serotonin Reuptake Inhibitor (SSRI) Monotherapy. Journal of pharmacy practice, 2020, Volume: 33, Issue:2 Topics: Anxiety; Depressive Disorder, Major; Female; Fluoxetine; Humans; Hydroxyzine; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Syndrome; Young Adult	2020
Brain Volume-Related Polymorphisms of the Glycogen Synthase Kinase-3β Gene and Their Effect on Antidepressant Treatment in Major Depressive Disorder. Neuropsychobiology, 2019, Volume: 78, Issue:3 Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Fluvoxamine; Genetic Predisposition to Disease; Genotype; Glycogen Synthase Kinase 3 beta; Hippocampus; Humans; Linkage Disequilibrium; Male; Middle Aged; Paroxetine; Polymorphism, Single Nucleotide	2019
Influence of baseline severity on the effects of SSRIs in depression: an item-based, patient-level post-hoc analysis. The lancet. Psychiatry, 2019, Volume: 6, Issue:9 Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Depression; Depressive Disorder, Major; Fluoxetine; Humans; Longitudinal Studies; Outcome Assessment, Health Care; Paroxetine; Placebos; Psychiatric Status Rating Scales; Reproducibility of Results; Selective Serotonin Reuptake Inhibitors; Sertraline; Severity of Illness Index	2019
Comparison of escitalopram and paroxetine in the treatment of major depressive disorder. International clinical psychopharmacology, 2013, Volume: 28, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Single-Blind Method; Treatment Outcome	2013
Depression impairs learning, whereas the selective serotonin reuptake inhibitor, paroxetine, impairs generalization in patients with major depressive disorder. Journal of affective disorders, 2013, Volume: 151, Issue:2 Topics: Adolescent; Adult; Cognition; Depressive Disorder, Major; Female; Generalization, Psychological; Humans; Learning Disabilities; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult	2013
Relationship between SSRI-induced sexual dysfunction and central serotonergic activity based on the loudness dependence of auditory evoked potentials. Psychopharmacology, 2014, Volume: 231, Issue:3 Topics: Acoustic Stimulation; Adult; Brain; Citalopram; Cross-Sectional Studies; Depressive Disorder, Major; Electroencephalography; Evoked Potentials, Auditory; Female; Humans; Hypnotics and Sedatives; Loudness Perception; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin; Sertraline; Sexual Dysfunction, Physiological	2014
Complexities of personalized medicine: how genes, drug-drug interactions, dosing schedules, and other factors can combine to produce clinically meaningful differences in a drug's effect. Journal of psychiatric practice, 2013, Volume: 19, Issue:5 Topics: Affective Disorders, Psychotic; Aged; Antipsychotic Agents; Depressive Disorder, Major; Dizziness; Drug Interactions; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Isoxazoles; Male; Paroxetine; Pharmacogenetics; Piperidines; Precision Medicine	2013
Occupancy of serotonin transporters in the amygdala by paroxetine in association with attenuation of left amygdala activation by negative faces in major depressive disorder. Psychiatry research, 2014, Feb-28, Volume: 221, Issue:2 Topics: Adult; Amygdala; Cocaine; Depressive Disorder, Major; Dose-Response Relationship, Drug; Facial Expression; Female; Functional Neuroimaging; Humans; Iodine Radioisotopes; Magnetic Resonance Imaging; Male; Middle Aged; Paroxetine; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Tomography, Emission-Computed, Single-Photon; Treatment Outcome	2014
Plasma brain derived neurotrophic factor levels and neuropsychological aspects of depressed patients treated with paroxetine. Panminerva medica, 2013, Volume: 55, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Biomarkers; Brain-Derived Neurotrophic Factor; Case-Control Studies; Cognition; Depressive Disorder, Major; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Memory; Middle Aged; Neuropsychological Tests; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome	2013
Lack of influence of rs4680 (COMT) and rs6276 (DRD2) on diagnosis and clinical outcomes in patients with major depression. International journal of psychiatry in clinical practice, 2014, Volume: 18, Issue:2 Topics: Adult; Antidepressive Agents, Second-Generation; Catechol O-Methyltransferase; Cyclohexanols; Depressive Disorder, Major; Epistasis, Genetic; Female; Humans; Male; Middle Aged; Paroxetine; Receptors, Dopamine D2; Republic of Korea; Treatment Outcome; Venlafaxine Hydrochloride	2014
Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a Chinese population. Therapeutic drug monitoring, 2014, Volume: 36, Issue:5 Topics: Adult; Asian People; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Female; Genotype; Glial Cell Line-Derived Neurotrophic Factor; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Single Nucleotide; Selective Serotonin Reuptake Inhibitors	2014
The influence of 5-HTTLPR genotype on the association between the plasma concentration and therapeutic effect of paroxetine in patients with major depressive disorder. PloS one, 2014, Volume: 9, Issue:5 Topics: Adolescent; Adult; Aged; Analysis of Variance; Depressive Disorder, Major; Female; Genotype; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome; Young Adult	2014
An investigation of temperament and character inventory items for predicting the response to paroxetine treatment in patients with major depressive disorder. Journal of affective disorders, 2014, Volume: 165 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Temperament; Young Adult	2014
Therapeutic reference range for plasma concentrations of paroxetine in patients with major depressive disorders. Therapeutic drug monitoring, 2014, Volume: 36, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Reference Values	2014
Benefit of slow titration of paroxetine to treat depression in the elderly. Human psychopharmacology, 2014, Volume: 29, Issue:6 Topics: Aged; Antidepressive Agents, Second-Generation; Computer Simulation; Cost-Benefit Analysis; Depressive Disorder, Major; Female; Humans; Italy; Male; Paroxetine; Patient Dropouts; Sensitivity and Specificity; Treatment Outcome	2014
Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up. Psychiatry research, 2015, Feb-28, Volume: 225, Issue:3 Topics: Adult; Citalopram; Cognitive Behavioral Therapy; Cohort Studies; Combined Modality Therapy; Depressive Disorder, Major; Female; Fluoxetine; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Paroxetine; Prospective Studies; Recurrence; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome	2015
Restoration of serotonin neuronal firing following long-term administration of bupropion but not paroxetine in olfactory bulbectomized rats. The international journal of neuropsychopharmacology, 2014, Oct-31, Volume: 18, Issue:4 Topics: Action Potentials; Animals; Antidepressive Agents, Second-Generation; Bupropion; CA3 Region, Hippocampal; Depressive Disorder, Major; Disease Models, Animal; Dorsal Raphe Nucleus; Locus Coeruleus; Male; Olfactory Bulb; Paroxetine; Piperazines; Pyramidal Cells; Pyridines; Rats, Sprague-Dawley; Receptor, Serotonin, 5-HT1A; Serotonergic Neurons; Serotonin Antagonists; Ventral Tegmental Area	2014
Urinary neopterine levels in patients with major depressive disorder: alterations after treatment with paroxetine and comparison with healthy controls. Psychiatria Danubina, 2015, Volume: 27, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Chromatography, Liquid; Depressive Disorder, Major; Drug Monitoring; Female; Humans; Male; Middle Aged; Neopterin; Paroxetine; Psychiatric Status Rating Scales; Treatment Outcome	2015
Real-world outcomes in patients with depression treated with duloxetine or a selective serotonin reuptake inhibitor in East Asia. Asia-Pacific psychiatry : official journal of the Pacific Rim College of Psychiatrists, 2016, Volume: 8, Issue:1 Topics: Adult; Asia, Eastern; Citalopram; Depressive Disorder, Major; Duloxetine Hydrochloride; Female; Fluoxetine; Humans; Male; Middle Aged; Pain; Paroxetine; Prospective Studies; Quality of Life; Regression Analysis; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin and Noradrenaline Reuptake Inhibitors; Sertraline; Severity of Illness Index; Treatment Outcome	2016
Restless legs syndrome associated with the combined use of duloxetine plus paroxetine. Journal of clinical psychopharmacology, 2015, Volume: 35, Issue:3 Topics: Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Duloxetine Hydrochloride; Female; Humans; Middle Aged; Paroxetine; Restless Legs Syndrome	2015
Changes in the Temperament and Character Inventory dimensions after paroxetine treatment in patients with major depressive disorder. Human psychopharmacology, 2015, Volume: 30, Issue:5 Topics: Adult; Character; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Personality Inventory; Selective Serotonin Reuptake Inhibitors; Temperament	2015
Persistent benefits of slow titration of paroxetine in a six-month follow-up. Human psychopharmacology, 2015, Volume: 30, Issue:5 Topics: Aged; Aged, 80 and over; Anxiety Disorders; Comorbidity; Depressive Disorder, Major; Female; Follow-Up Studies; Humans; Male; Outcome Assessment, Health Care; Paroxetine; Selective Serotonin Reuptake Inhibitors	2015
Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. Journal of affective disorders, 2015, Jul-15, Volume: 180 Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Evidence-Based Medicine; Female; Fluoxetine; Fluvoxamine; Humans; Male; Middle Aged; Moclobemide; Nortriptyline; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome	2015
Comparison of tolerance of venlafaxine, paroxetine and amitriptyline in depression therapy. Medical archives (Sarajevo, Bosnia and Herzegovina), 2015, Volume: 69, Issue:2 Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Drug Tolerance; Female; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Time Factors; Venlafaxine Hydrochloride; Young Adult	2015
Isn't It About Time to Employ Measurement-Based Care in Practice? The American journal of psychiatry, 2015, Volume: 172, Issue:10 Topics: Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Mianserin; Paroxetine	2015
No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility. BMJ (Clinical research ed.), 2015, Sep-16, Volume: 351 Topics: Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Paroxetine; Reproducibility of Results; Retraction of Publication as Topic; United States; Universities	2015
Exposure-outcome analysis in depressed patients treated with paroxetine using population pharmacokinetics. Drug design, development and therapy, 2015, Volume: 9 Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Area Under Curve; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Logistic Models; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Nonlinear Dynamics; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Young Adult	2015
Restoring Study 329: results differ with the adverse event classification system used. BMJ (Clinical research ed.), 2015, Oct-14, Volume: 351 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Imipramine; Paroxetine	2015
Authors' reply to Sasich and Linden. BMJ (Clinical research ed.), 2015, Oct-14, Volume: 351 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Imipramine; Paroxetine	2015
Paroxetine and Study 329: what we already knew and when. BMJ (Clinical research ed.), 2015, Oct-14, Volume: 351 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Imipramine; Paroxetine	2015
Both paroxetine and imipramine appear to be ineffective in adolescents with major depression, furthermore doubts have risen about their safety. Evidence-based medicine, 2016, Volume: 21, Issue:3 Topics: Adolescent; Antidepressive Agents; Depressive Disorder, Major; Humans; Imipramine; Paroxetine	2016
Influence of the cytochrome P450 2D6 10/10 genotype on the pharmacokinetics of paroxetine in Japanese patients with major depressive disorder: a population pharmacokinetic analysis. Pharmacogenetics and genomics, 2016, Volume: 26, Issue:9 Topics: Adolescent; Adult; Aged; Asian People; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Female; Gene Frequency; Humans; Japan; Male; Middle Aged; Paroxetine; Pharmacogenomic Variants; Polymorphism, Single Nucleotide; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Young Adult	2016
Decreased sensitivity to paroxetine-induced inhibition of peripheral blood mononuclear cell growth in depressed and antidepressant treatment-resistant patients. Translational psychiatry, 2016, 05-31, Volume: 6, Issue:5 Topics: Adult; Biomarkers; Cell Proliferation; Depressive Disorder, Major; Depressive Disorder, Treatment-Resistant; Female; Humans; Integrin beta3; Male; Mianserin; Middle Aged; Mirtazapine; Monocytes; Paroxetine; Peptide Fragments; Serotonin Plasma Membrane Transport Proteins	2016
A mega-analysis of fixed-dose trials reveals dose-dependency and a rapid onset of action for the antidepressant effect of three selective serotonin reuptake inhibitors. Translational psychiatry, 2016, 06-07, Volume: 6, Issue:6 Topics: Adult; Citalopram; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Paroxetine; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome	2016
An attempt to construct a 7-item short version of the temperament and character inventory to predict the treatment response of patients with depression; a validation study. BMC psychiatry, 2016, 08-12, Volume: 16 Topics: Adult; Character; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Psychiatric Status Rating Scales; Temperament; Treatment Outcome	2016
Purine and pyrimidine metabolism: Convergent evidence on chronic antidepressant treatment response in mice and humans. Scientific reports, 2016, 10-12, Volume: 6 Topics: Animals; Antidepressive Agents; Behavior, Animal; Depressive Disorder, Major; Hippocampus; Humans; Male; Metabolome; Mice; Mice, Inbred DBA; Paroxetine; Proteome; Purines; Pyrimidines; Selective Serotonin Reuptake Inhibitors; Swimming; Time Factors	2016
Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient. Revue neurologique, 2016, Volume: 172, Issue:12 Topics: Aged; Depressive Disorder, Major; Drug Interactions; Humans; Indans; Male; Monoamine Oxidase Inhibitors; Parkinson Disease; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome	2016
Alternative splicing of SMPD1 coding for acid sphingomyelinase in major depression. Journal of affective disorders, 2017, Volume: 209 Topics: Adult; Aged; Alternative Splicing; Antidepressive Agents; Biomarkers; Depressive Disorder, Major; Female; Fluoxetine; Gene Expression Regulation, Enzymologic; Humans; Male; Middle Aged; Paroxetine; Polymerase Chain Reaction; Sphingomyelin Phosphodiesterase	2017
Biological profiling of prospective antidepressant response in major depressive disorder: Associations with (neuro)inflammation, fatty acid metabolism, and amygdala-reactivity. Psychoneuroendocrinology, 2017, Volume: 79 Topics: Adult; Amygdala; Antidepressive Agents; C-Reactive Protein; Depressive Disorder, Major; Fatty Acids; Female; Humans; Inflammation; Lipid Metabolism; Magnetic Resonance Imaging; Male; Middle Aged; Paroxetine; Prospective Studies	2017
Personalizing the care of geriatric depression. The American journal of psychiatry, 2008, Volume: 165, Issue:7 Topics: Aged; Alzheimer Disease; Antidepressive Agents, Tricyclic; Brain; Case Management; Comorbidity; Depressive Disorder, Major; Health Services for the Aged; Humans; Magnetic Resonance Imaging; Nortriptyline; Paroxetine; Patient-Centered Care; Psychology; Selective Serotonin Reuptake Inhibitors; Socioeconomic Factors	2008
A case with occurring adverse effects when cross-over titration from fluvoxamine to paroxetine associated with increasing the plasma fluvoxamine level in major depressive disorder. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2009, Volume: 10, Issue:4 Pt 2 Topics: Adult; Antidepressive Agents, Second-Generation; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combination; Female; Fluvoxamine; Humans; Paroxetine	2009
CYP2D6 and ABCB1 genetic variability: influence on paroxetine plasma level and therapeutic response. Therapeutic drug monitoring, 2008, Volume: 30, Issue:4 Topics: Adolescent; Adult; Aged; Algorithms; Analysis of Variance; Antidepressive Agents, Second-Generation; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP2D6; Depressive Disorder, Major; Female; Gas Chromatography-Mass Spectrometry; Genetic Variation; Humans; Linear Models; Male; Middle Aged; Paroxetine; Phenotype; Psychiatric Status Rating Scales; Young Adult	2008
Flat dose-response curves for efficacy: what do they mean to the clinician? Journal of psychiatric practice, 2008, Volume: 14, Issue:4 Topics: Attitude of Health Personnel; Cyclohexanols; Depressive Disorder, Major; Desvenlafaxine Succinate; Dose-Response Relationship, Drug; Drug Administration Schedule; Fluoxetine; Humans; Neurotransmitter Uptake Inhibitors; Paroxetine; Physicians; Randomized Controlled Trials as Topic; Sertraline; Treatment Outcome; United States; United States Food and Drug Administration	2008
Serotonin transporter gene promoter polymorphisms modify the association between paroxetine serotonin transporter occupancy and clinical response in major depressive disorder. Pharmacogenetics and genomics, 2009, Volume: 19, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Base Sequence; Depressive Disorder, Major; Diencephalon; DNA Primers; Female; Genotype; Humans; Male; Mesencephalon; Middle Aged; Paroxetine; Pharmacogenetics; Polymorphism, Genetic; Promoter Regions, Genetic; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Tomography, Emission-Computed, Single-Photon	2009
The catechol-O-methyltransferase Val(108/158)Met polymorphism affects antidepressant response to paroxetine in a naturalistic setting. Psychopharmacology, 2009, Volume: 203, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Catechol O-Methyltransferase; Catecholamines; Depressive Disorder, Major; Female; Heterozygote; Homozygote; Humans; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Time Factors; Treatment Outcome	2009
Successful management of depression with reboxetine in a patient who developed Parkinsonism related to paroxetine use. Journal of psychopharmacology (Oxford, England), 2010, Volume: 24, Issue:4 Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Male; Middle Aged; Morpholines; Parkinson Disease, Secondary; Paroxetine; Psychiatric Status Rating Scales; Reboxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Treatment Outcome	2010
5-HT2A gene variants influence specific and different aspects of antidepressant response in Japanese and Italian mood disorder patients. Psychiatry research, 2009, May-15, Volume: 167, Issue:1-2 Topics: Adult; Antidepressive Agents; Asian People; Depressive Disorder; Depressive Disorder, Major; Female; Fluvoxamine; Gene Frequency; Genetic Variation; Genotype; Humans; Italy; Male; Middle Aged; Paroxetine; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; White People	2009
Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment. Psychiatry research, 2009, Jul-15, Volume: 173, Issue:1 Topics: Adult; Antidepressive Agents; Brain; Brain Mapping; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Fluorodeoxyglucose F18; Functional Laterality; Glucose; Gyrus Cinguli; Humans; Image Processing, Computer-Assisted; Male; Mesencephalon; Middle Aged; Paroxetine; Positron-Emission Tomography; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2009
Efficacy of SSRIs on cognition of Alzheimer's disease patients treated with cholinesterase inhibitors. International psychogeriatrics, 2010, Volume: 22, Issue:1 Topics: Aged; Alzheimer Disease; Cholinesterase Inhibitors; Citalopram; Cognition; Cognition Disorders; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Movement Disorders; Neuropsychological Tests; Paroxetine; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index	2010
5-HTR1A, 5-HTR2A, 5-HTR6, TPH1 and TPH2 polymorphisms and major depression. Neuroreport, 2009, Aug-05, Volume: 20, Issue:12 Topics: Adolescent; Adult; Aged; Citalopram; Depressive Disorder, Major; Fluoxetine; Humans; Middle Aged; Paroxetine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT2A; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Tryptophan Hydroxylase; Young Adult	2009
Comments on "An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606 in patients with treatment-refractory major depressive disorder". Journal of clinical psychopharmacology, 2009, Volume: 29, Issue:4 Topics: Antidepressive Agents; Depressive Disorder, Major; Double-Blind Method; Drug Resistance; Excitatory Amino Acid Antagonists; Humans; Infusions, Intravenous; Paroxetine; Piperidines; Psychiatric Status Rating Scales; Randomized Controlled Trials as Topic; Receptors, N-Methyl-D-Aspartate; Receptors, sigma; Research Design; Sigma-1 Receptor; Treatment Outcome	2009
Association of a functional polymorphism in the adrenomedullin gene (ADM) with response to paroxetine. The pharmacogenomics journal, 2010, Volume: 10, Issue:2 Topics: Adrenomedullin; Animals; Antidepressive Agents; Cell Line; Depressive Disorder, Major; Paroxetine; Polymorphism, Genetic; Polymorphism, Single Nucleotide; Raphe Nuclei; Rats	2010
Effects of paroxetine and sertraline on low-density lipoprotein cholesterol: an observational cohort study. CNS drugs, 2009, Volume: 23, Issue:10 Topics: Adult; Cardiovascular Diseases; Cholesterol, LDL; Cohort Studies; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Risk Factors; Sertraline; Time Factors	2009
The treatment of SSRI-resistant depression in adolescents (TORDIA): in search of the best next step. Depression and anxiety, 2009, Volume: 26, Issue:10 Topics: Adolescent; Antidepressive Agents; Citalopram; Cognitive Behavioral Therapy; Combined Modality Therapy; Comorbidity; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Female; Fluoxetine; Humans; Male; Multicenter Studies as Topic; Paroxetine; Personality Assessment; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Suicide; Suicide Prevention; Suicide, Attempted; Venlafaxine Hydrochloride	2009
HTR2A is associated with SSRI response in major depressive disorder in a Japanese cohort. Neuromolecular medicine, 2010, Volume: 12, Issue:3 Topics: Asian People; Depressive Disorder, Major; Fluvoxamine; Genotype; Haplotypes; Humans; Linkage Disequilibrium; Paroxetine; Polymorphism, Single Nucleotide; Receptor, Serotonin, 5-HT2A; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome	2010
Nonadherence to paroxetine: a study based on monitoring plasma paroxetine levels. Journal of clinical psychopharmacology, 2010, Volume: 30, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Monitoring; Female; Humans; Male; Medication Adherence; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors	2010
Manic switch and serotonin syndrome induced by augmentation of paroxetine with methylphenidate in a patient with major depression. Progress in neuro-psychopharmacology & biological psychiatry, 2010, May-30, Volume: 34, Issue:4 Topics: Adolescent; Bipolar Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Male; Methylphenidate; Paroxetine; Serotonin Syndrome; Treatment Outcome	2010
Sustained stress-induced changes in mice as a model for chronic depression. Psychopharmacology, 2010, Volume: 210, Issue:3 Topics: Animals; Cell Proliferation; Chronic Disease; Depressive Disorder, Major; Disease Models, Animal; Hippocampus; Male; Mice; Mice, Inbred C57BL; Paroxetine; Stress, Psychological; Time Factors	2010
Delusion of Cotard's syndrome successfully treated with a dopamine agonist. The Journal of neuropsychiatry and clinical neurosciences, 2010,Spring, Volume: 22, Issue:2 Topics: Antidepressive Agents, Second-Generation; Anxiety; Benzothiazoles; Delusions; Depressive Disorder, Major; Dopamine Agonists; Female; Follow-Up Studies; Humans; Middle Aged; Paroxetine; Pramipexole; Recurrence; Syndrome; Treatment Outcome	2010
A structural mean model to allow for noncompliance in a randomized trial comparing 2 active treatments. Biostatistics (Oxford, England), 2011, Volume: 12, Issue:2 Topics: Algorithms; Bias; Computer Simulation; Depressive Disorder, Major; Double-Blind Method; Fluoxetine; Humans; Linear Models; Medication Adherence; Models, Statistical; Multicenter Studies as Topic; Paroxetine; Randomized Controlled Trials as Topic; Treatment Outcome	2011
On the three-arm non-inferiority trial including a placebo with a prespecified margin. Statistics in medicine, 2011, Feb-10, Volume: 30, Issue:3 Topics: Algorithms; Antidepressive Agents; Computer Simulation; Confidence Intervals; Depressive Disorder, Major; Double-Blind Method; Duloxetine Hydrochloride; Humans; Models, Statistical; Monte Carlo Method; Multicenter Studies as Topic; Normal Distribution; Paroxetine; Placebos; Randomized Controlled Trials as Topic; Sample Size; Thiophenes; Treatment Outcome	2011
Genome-wide expression profiling of human lymphoblastoid cell lines identifies CHL1 as a putative SSRI antidepressant response biomarker. Pharmacogenomics, 2011, Volume: 12, Issue:2 Topics: Adult; Antidepressive Agents; Biomarkers, Pharmacological; Cell Adhesion Molecules; Cell Line, Tumor; Depressive Disorder, Major; Female; Gene Expression Profiling; Genome-Wide Association Study; Genome, Human; Humans; Membrane Proteins; Paroxetine; Selective Serotonin Reuptake Inhibitors	2011
Hallucination induced by paroxetine discontinuation in patients with major depressive disorders. Psychiatry and clinical neurosciences, 2011, Volume: 65, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Dizziness; Female; Hallucinations; Headache; Humans; Nausea; Paroxetine; Substance Withdrawal Syndrome	2011
Tamoxifen-SSRIs interaction: clinical manifestations of inhibition and lack of inhibition of CYP2D6. Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 2011, Volume: 23, Issue:2 Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Carcinoma, Ductal; Citalopram; Cytochrome P-450 CYP2D6 Inhibitors; Depressive Disorder, Major; Drug Interactions; Female; Hot Flashes; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Tamoxifen	2011
Association between plasma paroxetine concentration and changes in plasma brain‐derived neurotrophic factor levels in patients with major depressive disorder. Human psychopharmacology, 2011, Volume: 26, Issue:3 Topics: Adolescent; Adult; Aged; Biomarkers; Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Young Adult	2011
Possible association between ubiquitin-specific peptidase 46 gene and major depressive disorders in the Japanese population. Journal of affective disorders, 2011, Volume: 133, Issue:1-2 Topics: Adult; Asian People; Case-Control Studies; Circadian Clocks; Depressive Disorder, Major; Endopeptidases; Female; Fluvoxamine; Genetic Predisposition to Disease; Genotype; Haplotypes; Humans; Male; Paroxetine; Polymorphism, Single Nucleotide; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome; Ubiquitin	2011
A rare case of male hysteria - hemiparesis successfully treated with amitriptyline. Psychiatria Danubina, 2011, Volume: 23, Issue:3 Topics: Adult; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Brain; Bromazepam; Depressive Disorder, Major; Humans; Hysteria; Lorazepam; Magnetic Resonance Imaging; Male; Paresis; Paroxetine; Treatment Outcome	2011
Inverse correlation between clinical response to paroxetine and plasma drug concentration in patients with major depressive disorders. Human psychopharmacology, 2011, Volume: 26, Issue:8 Topics: Adult; Antidepressive Agents, Second-Generation; Biomarkers; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2011
Odd odds. The Journal of clinical psychiatry, 2011, Volume: 72, Issue:11 Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Mental Disorders; Paroxetine; Randomized Controlled Trials as Topic; Suicide	2011
The association between sunshine duration and paroxetine response time in patients with major depressive disorder. Journal of affective disorders, 2012, Volume: 136, Issue:3 Topics: Adult; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Reaction Time; Seasons; Selective Serotonin Reuptake Inhibitors; Sunlight; Time Factors	2012
Visual and auditory hallucinations during normal use of paroxetine for treatment of major depressive disorder. The Journal of neuropsychiatry and clinical neurosciences, 2011,Fall, Volume: 23, Issue:4 Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Hallucinations; Humans; Paroxetine	2011
Can Minnesota Multiphasic Personality Inventory-2 predict response to selective serotonin reuptake inhibitors in depressed outpatients? International clinical psychopharmacology, 2012, Volume: 27, Issue:3 Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Ambulatory Care; Antidepressive Agents, Second-Generation; Chi-Square Distribution; Citalopram; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Israel; Logistic Models; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Paroxetine; Patient Selection; Personality Assessment; Predictive Value of Tests; Psychiatric Status Rating Scales; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Time Factors; Treatment Outcome; Young Adult	2012
Genome-wide association study of SSRI/SNRI-induced sexual dysfunction in a Japanese cohort with major depression. Psychiatry research, 2012, Aug-15, Volume: 198, Issue:3 Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Aged, 80 and over; Asian People; Cohort Studies; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Genome-Wide Association Study; Genotype; GPI-Linked Proteins; Humans; Male; Middle Aged; Milnacipran; Neural Cell Adhesion Molecules; Paroxetine; Polymorphism, Single Nucleotide; Selective Serotonin Reuptake Inhibitors; Sexual Dysfunction, Physiological; Sexual Dysfunctions, Psychological	2012
Sex differences in human lymphoblastoid cells sensitivities to antipsychotic drugs. Journal of molecular neuroscience : MN, 2013, Volume: 49, Issue:3 Topics: Anti-Inflammatory Agents; Antidepressive Agents; Antineoplastic Agents; Antipsychotic Agents; Cell Division; Cell Survival; Cells, Cultured; Cytostatic Agents; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Resistance; Dystonic Disorders; Female; Haloperidol; Humans; Lymphocytes; Male; Paroxetine; Risperidone; Schizophrenia; Sex Characteristics; Sex Distribution	2013
Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics, 2012, Volume: 13, Issue:10 Topics: Biomarkers, Pharmacological; Cell Adhesion Molecules; Cell Line, Transformed; Depressive Disorder, Major; Female; Gene Expression Profiling; Gene Expression Regulation; Genome, Human; Humans; MicroRNAs; Paroxetine; Selective Serotonin Reuptake Inhibitors	2012
DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study. Journal of clinical psychopharmacology, 2012, Volume: 32, Issue:5 Topics: Brain-Derived Neurotrophic Factor; Depressive Disorder, Major; Genotype; Humans; Paroxetine; Pharmacogenetics; Polymorphism, Single Nucleotide; Receptors, Dopamine D3; Selective Serotonin Reuptake Inhibitors; Treatment Outcome	2012
The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies. The Journal of clinical psychiatry, 2012, Volume: 73, Issue:11 Topics: Adolescent; Adult; Anti-Anxiety Agents; Antidepressive Agents; Antidiuretic Hormone Receptor Antagonists; Anxiety Disorders; Citalopram; Clinical Trials, Phase II as Topic; Depressive Disorder, Major; Double-Blind Method; Female; Humans; Indoles; Male; Middle Aged; Multicenter Studies as Topic; Paroxetine; Pyrrolidines; Randomized Controlled Trials as Topic; Recurrence; Treatment Outcome; Young Adult	2012
[Improvement of tardive dyskinesia after treatment with olanzapine]. Psychiatrische Praxis, 2002, Volume: 29, Issue:6 Topics: Affective Disorders, Psychotic; Aged; Benzodiazepines; Depressive Disorder, Major; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Haloperidol; Humans; Neurologic Examination; Olanzapine; Paroxetine; Patient Admission; Pirenzepine	2002
Paroxetine in the treatment of adolescent major depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, Volume: 41, Issue:11 Topics: Adolescent; Depressive Disorder, Major; Drug Monitoring; Humans; Imipramine; Paroxetine; Selective Serotonin Reuptake Inhibitors	2002
Paroxetine in the treatment of adolescent major depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, Volume: 41, Issue:11 Topics: Adolescent; Depressive Disorder, Major; Drug Monitoring; Humans; Imipramine; Paroxetine; Selective Serotonin Reuptake Inhibitors	2002
A retrospective analysis of the revocation of prior authorization restrictions and the use of antidepressant medications for treating major depressive disorder. Clinical therapeutics, 2002, Volume: 24, Issue:11 Topics: Adult; California; Depressive Disorder, Major; Drug Costs; Drug Utilization Review; Female; Fluoxetine; Humans; Insurance Claim Review; Male; Medicaid; Middle Aged; Paroxetine; Retrospective Studies; Selective Serotonin Reuptake Inhibitors	2002
Depression after cardiac transplant treated with interpersonal psychotherapy and paroxetine. American journal of psychotherapy, 2002, Volume: 56, Issue:4 Topics: Aged; Depressive Disorder, Major; Heart Transplantation; Humans; Interpersonal Relations; Male; Paroxetine; Selective Serotonin Reuptake Inhibitors	2002
Serotonin transporter modulation in blood lymphocytes from patients with major depression. Cellular and molecular neurobiology, 2002, Volume: 22, Issue:5-6 Topics: Adrenergic alpha-Antagonists; Adult; Antidepressive Agents, Second-Generation; Brain; Carrier Proteins; Depressive Disorder, Major; Down-Regulation; Female; Fluoxetine; Humans; Lymphocytes; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mianserin; Mirtazapine; Nerve Tissue Proteins; Neuroimmunomodulation; Paroxetine; Radioligand Assay; Serotonin; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome; Up-Regulation	2002
State markers of depression in sleep EEG: dependency on drug and gender in patients treated with tianeptine or paroxetine. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2003, Volume: 28, Issue:2 Topics: Adult; Aged; Analysis of Variance; Biomarkers; Depressive Disorder, Major; Electroencephalography; Female; Humans; Male; Middle Aged; Paroxetine; Patients; Sex Factors; Sleep; Thiazepines	2003
5-HT(2A) receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study. Psychopharmacology, 2003, Volume: 167, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Brain; Case-Control Studies; Depressive Disorder, Major; Dopamine Antagonists; Female; Fluorine Radioisotopes; Humans; Ligands; Male; Middle Aged; Paroxetine; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Spiperone; Tomography, Emission-Computed	2003
Minor strokes related to paroxetine discontinuation in an elderly subject: emergent adverse events. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2003, Volume: 48, Issue:4 Topics: Aged; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Humans; Magnetic Resonance Imaging; Male; Paroxetine; Severity of Illness Index; Stroke; Substance Withdrawal Syndrome	2003
Differential period of onset of action of fluvoxamine, paroxetine and milnacipran for depression. Human psychopharmacology, 2003, Volume: 18, Issue:6 Topics: Antidepressive Agents; Bipolar Disorder; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Outpatients; Paroxetine; Psychiatric Status Rating Scales; Retrospective Studies; Time Factors; Treatment Outcome	2003
Psychopharmacological treatment of major depressive disorder in children and adolescents. JAMA, 2003, Aug-27, Volume: 290, Issue:8 Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline; Suicide	2003
The effect of alexithymic features on response to antidepressant medication in patients with major depression. Depression and anxiety, 2003, Volume: 18, Issue:2 Topics: Adult; Affective Symptoms; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Paroxetine; Surveys and Questionnaires	2003
Paroxetine treatment of mood and anxiety disorders in children and adolescents. Psychopharmacology bulletin, 2003,Spring, Volume: 37 Suppl 1 Topics: Adolescent; Antidepressive Agents, Second-Generation; Anxiety Disorders; Child; Depressive Disorder, Major; Humans; Mood Disorders; Paroxetine; Phobic Disorders	2003
alpha1-acid glycoprotein in late-life depression: relationship to medical burden and genetics. Journal of geriatric psychiatry and neurology, 2003, Volume: 16, Issue:4 Topics: Aged; Aged, 80 and over; Alleles; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cognition Disorders; Cost of Illness; Depressive Disorder, Major; Double-Blind Method; Female; Gene Expression; Humans; Male; Middle Aged; Neuropsychological Tests; Nortriptyline; Orosomucoid; Paroxetine; Severity of Illness Index; Surveys and Questionnaires	2003
Differential effects of milnacipran, fluvoxamine and paroxetine for depression, especially in gender. European psychiatry : the journal of the Association of European Psychiatrists, 2003, Volume: 18, Issue:8 Topics: Adrenergic Uptake Inhibitors; Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Cohort Studies; Cyclopropanes; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Milnacipran; Paroxetine; Personality Inventory; Psychometrics; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Sex Factors; Treatment Outcome	2003
Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Archives of general psychiatry, 2004, Volume: 61, Issue:1 Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Blood Glucose; Brain Mapping; Cerebral Cortex; Cognitive Behavioral Therapy; Depressive Disorder, Major; Energy Metabolism; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Frontal Lobe; Humans; Limbic System; Male; Middle Aged; Nerve Net; Neural Pathways; Outcome and Process Assessment, Health Care; Paroxetine; Personality Inventory; Prefrontal Cortex; Sensitivity and Specificity; Tomography, Emission-Computed	2004
Paroxetine and the FDA. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, Volume: 43, Issue:2 Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Evidence-Based Medicine; Humans; Paroxetine; Self-Injurious Behavior; Suicide; United States; United States Food and Drug Administration	2004
Paroxetine and the FDA. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, Volume: 43, Issue:2 Topics: Adolescent; Antidepressive Agents; Depressive Disorder, Major; Evidence-Based Medicine; Humans; Paroxetine; Suicide; United States; United States Food and Drug Administration	2004
Paroxetine and the FDA. Journal of the American Academy of Child and Adolescent Psychiatry, 2004, Volume: 43, Issue:2 Topics: Antidepressive Agents; Depressive Disorder, Major; Drug Industry; Humans; Paroxetine; Suicide; United States; United States Food and Drug Administration	2004
Delirium induced by abrupt discontinuation of paroxetine. The Journal of neuropsychiatry and clinical neurosciences, 2004,Winter, Volume: 16, Issue:1 Topics: Aged; Antidepressive Agents, Second-Generation; Delirium; Depressive Disorder, Major; Female; Humans; Paroxetine; Substance Withdrawal Syndrome	2004
Limbic-frontal circuitry in major depression: a path modeling metanalysis. NeuroImage, 2004, Volume: 22, Issue:1 Topics: Algorithms; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Drug Resistance; Electroconvulsive Therapy; Fluorodeoxyglucose F18; Frontal Lobe; Humans; Image Processing, Computer-Assisted; Limbic System; Models, Neurological; Nerve Net; Paroxetine; Radiopharmaceuticals; Tomography, Emission-Computed	2004
Cost and effectiveness of venlafaxine extended-release and selective serotonin reuptake inhibitors in the acute phase of outpatient treatment for major depressive disorder. Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:5 Topics: Activities of Daily Living; Acute Disease; Ambulatory Care; Cost-Benefit Analysis; Cyclohexanols; Decision Support Techniques; Delayed-Action Preparations; Depressive Disorder, Major; Double-Blind Method; Drug Costs; Female; Fluoxetine; Fluvoxamine; Humans; Male; Paroxetine; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; Retrospective Studies; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Venlafaxine Hydrochloride	2004
Lipid metabolism and insulin resistance in depressed patients: significance of weight, hypercortisolism, and antidepressant treatment. Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Amitriptyline; Analysis of Variance; Antidepressive Agents; Blood Glucose; Body Mass Index; Cholesterol; Circadian Rhythm; Coronary Disease; Depressive Disorder, Major; Female; Humans; Hydrocortisone; Hypothalamo-Hypophyseal System; Insulin Resistance; Lipids; Lipoproteins; Male; Metabolic Syndrome; Middle Aged; Obesity; Paroxetine; Pituitary-Adrenal System; Risk Factors; Triglycerides	2004
SSRI-induced enuresis: a case report. Journal of clinical psychopharmacology, 2004, Volume: 24, Issue:5 Topics: Adult; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Enuresis; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors	2004
The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. The pharmacogenomics journal, 2005, Volume: 5, Issue:1 Topics: Adult; Catechol O-Methyltransferase; Depressive Disorder, Major; Female; Humans; Male; Methionine; Mianserin; Middle Aged; Mirtazapine; Paroxetine; Polymorphism, Genetic; Time Factors; Valine	2005
Antidepressant treatment-associated behavioural expression of hypomania: a case series. Progress in neuro-psychopharmacology & biological psychiatry, 2004, Volume: 28, Issue:7 Topics: Adult; Affect; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bipolar Disorder; Depressive Disorder, Major; Female; Humans; Irritable Mood; Ischemic Attack, Transient; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Stroke	2004
Improvement of dry mouth by replacing paroxetine with fluvoxamine. The Annals of pharmacotherapy, 2005, Volume: 39, Issue:3 Topics: Aged; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Paroxetine; Receptors, Muscarinic; Selective Serotonin Reuptake Inhibitors; Xerostomia	2005
Body pain and treatment response in late-life depression. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2005, Volume: 13, Issue:3 Topics: Activities of Daily Living; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depressive Disorder, Major; Epidemiologic Methods; Female; Humans; Male; Pain; Pain Management; Pain Measurement; Paroxetine; Psychotherapy; Suicide; Time Factors	2005
Effect of mirtazapine treatment on serotonin transporter in blood peripheral lymphocytes of major depression patients. International immunopharmacology, 2005, Volume: 5, Issue:6 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Cell Membrane; Depressive Disorder, Major; Female; Humans; Hydroxyindoleacetic Acid; Kinetics; Lymphocytes; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mianserin; Middle Aged; Mirtazapine; Nerve Tissue Proteins; Norepinephrine; Paroxetine; Psychiatric Status Rating Scales; Serotonin; Serotonin Plasma Membrane Transport Proteins	2005
Positional asphyxiation from paroxetine. The American journal of psychiatry, 2005, Volume: 162, Issue:6 Topics: Adult; Asphyxia; Depressive Disorder, Major; Humans; Male; Paroxetine; Phobic Disorders; Poisoning; Posture; Selective Serotonin Reuptake Inhibitors	2005
Interpersonal psychotherapy for depression with panic spectrum symptoms: a pilot study. Depression and anxiety, 2005, Volume: 21, Issue:3 Topics: Anxiety Disorders; Citalopram; Depressive Disorder, Major; Female; Fluoxetine; Humans; Interpersonal Relations; Male; Panic Disorder; Paroxetine; Pilot Projects; Problem Solving; Psychotherapy; Quality of Life; Selective Serotonin Reuptake Inhibitors	2005
What happens with adverse events during 6 months of treatment with selective serotonin reuptake inhibitors? The Journal of clinical psychiatry, 2005, Volume: 66, Issue:7 Topics: Adult; Adverse Drug Reaction Reporting Systems; Data Interpretation, Statistical; Depressive Disorder, Major; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Outcome Assessment, Health Care; Paroxetine; Patient Dropouts; Recurrence; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Sex Factors; Time Factors; Treatment Outcome	2005
Late-onset major depression: clinical and treatment-response variability. International journal of geriatric psychiatry, 2005, Volume: 20, Issue:7 Topics: Activities of Daily Living; Age of Onset; Aged; Analysis of Variance; Antidepressive Agents, Second-Generation; Cognition Disorders; Depressive Disorder, Major; Female; Humans; Male; Neuropsychological Tests; Paroxetine; Prognosis; Psychiatric Status Rating Scales; Recurrence; Time Factors; Treatment Outcome	2005
Trajectories of treatment response in late-life depression: psychosocial and clinical correlates. Journal of clinical psychopharmacology, 2005, Volume: 25, Issue:4 Suppl 1 Topics: Age Factors; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disorder, Major; Female; Humans; Logistic Models; Male; Middle Aged; Nortriptyline; Paroxetine; Psychological Tests; Psychotherapy; Socioeconomic Factors; Treatment Outcome	2005
Postpartum depression without delivering a child? Acta psychiatrica Scandinavica, 2005, Volume: 112, Issue:3 Topics: Alprazolam; Anti-Anxiety Agents; Depression, Postpartum; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Family; Female; Humans; Hysterectomy; Middle Aged; Paroxetine; Risperidone; Selective Serotonin Reuptake Inhibitors; Serotonin Antagonists; Suicide, Attempted	2005
An open-label study of duloxetine for the treatment of major depressive disorder: comparison of switching versus initiating treatment approaches. Journal of clinical psychopharmacology, 2005, Volume: 25, Issue:6 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Cyclohexanols; Depressive Disorder, Major; Dose-Response Relationship, Drug; Duloxetine Hydrochloride; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Sertraline; Thiophenes; Treatment Outcome; Venlafaxine Hydrochloride	2005
Analysis of COMT gene (Val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of European origin. Journal of affective disorders, 2006, Volume: 90, Issue:2-3 Topics: Antidepressive Agents, Second-Generation; Biological Availability; Catechol O-Methyltransferase; Citalopram; Depressive Disorder, Major; Dopamine; Ethnicity; Female; Fluvoxamine; Follow-Up Studies; Frontal Lobe; Genetic Carrier Screening; Genotype; Humans; Male; Methionine; Paroxetine; Personality Inventory; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Treatment Outcome; Valine	2006
Clinical efficacy of agomelatine in depression: the evidence. International clinical psychopharmacology, 2006, Volume: 21 Suppl 1 Topics: Acetamides; Adolescent; Adult; Aged; Antidepressive Agents; Controlled Clinical Trials as Topic; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drugs, Investigational; Humans; Middle Aged; Multicenter Studies as Topic; Paroxetine; Treatment Outcome	2006
Digitalis intoxication induced by paroxetine co-administration. Lancet (London, England), 2006, Mar-04, Volume: 367, Issue:9512 Topics: Aged; Antidepressive Agents, Second-Generation; Atrial Fibrillation; Depressive Disorder, Major; Digoxin; Drug Interactions; Fatal Outcome; Female; Humans; Paroxetine	2006
Antidepressant therapy and C-reactive protein levels. The British journal of psychiatry : the journal of mental science, 2006, Volume: 188 Topics: Adult; Aged; C-Reactive Protein; Depressive Disorder, Major; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sertraline	2006
Maintenance treatment of depression in old age. The New England journal of medicine, 2006, Jun-08, Volume: 354, Issue:23 Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Paroxetine; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index	2006
Maintenance treatment of depression in old age. The New England journal of medicine, 2006, Jun-08, Volume: 354, Issue:23 Topics: Aged; Combined Modality Therapy; Depressive Disorder, Major; Humans; Paroxetine; Psychotherapy; Secondary Prevention; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index	2006
Bupropion augmentation in the treatment of chronic fatigue syndrome with coexistent major depression episode. Pharmacopsychiatry, 2006, Volume: 39, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder, Major; Fatigue Syndrome, Chronic; Female; Humans; Paroxetine; Psychiatric Status Rating Scales	2006
Delirium and multiple electrolyte abnormalities associated with high dose paroxetine exposure. Psychiatry and clinical neurosciences, 2006, Volume: 60, Issue:5 Topics: Antidepressive Agents, Second-Generation; Delirium; Depressive Disorder, Major; Dose-Response Relationship, Drug; Humans; Hyponatremia; Inappropriate ADH Syndrome; Male; Middle Aged; Myelodysplastic Syndromes; Paroxetine; Water-Electrolyte Imbalance	2006
Induction of a mixed depressive episode during rTMS treatment in a patient with refractory major depression. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2006, Volume: 7, Issue:4 Topics: Adult; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antimanic Agents; Depressive Disorder, Major; Female; Humans; Methadone; Mood Disorders; Narcotics; Opipramol; Paroxetine; Prazepam; Psychiatric Status Rating Scales; Serotonin Syndrome; Severity of Illness Index; Substance-Related Disorders; Transcranial Magnetic Stimulation; Trazodone; Valproic Acid	2006
Altered HDAC5 and CREB mRNA expressions in the peripheral leukocytes of major depression. Progress in neuro-psychopharmacology & biological psychiatry, 2007, Apr-13, Volume: 31, Issue:3 Topics: Adult; Aged; Case-Control Studies; CREB-Binding Protein; Depressive Disorder, Major; Female; Gene Expression Regulation; Histone Deacetylases; Humans; Leukocytes; Male; Middle Aged; Paroxetine; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Statistics, Nonparametric	2007
L-thyroxine augmentation of serotonergic antidepressants in female patients with refractory depression. Journal of affective disorders, 2007, Volume: 103, Issue:1-3 Topics: Adult; Bipolar Disorder; Clomipramine; Depressive Disorder, Major; Drug Resistance; Drug Therapy, Combination; Female; Fluoxetine; Humans; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Thyroxine; Treatment Outcome	2007
The treatment of child and adolescent depression: a matter of concern? Acta psychiatrica Scandinavica, 2007, Volume: 115, Issue:3 Topics: Adolescent; Antidepressive Agents; Child; Depressive Disorder, Major; Drug Therapy; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors; Suicide, Attempted	2007
Antidepressant response in the elderly. Psychiatry research, 2007, Jul-30, Volume: 152, Issue:1 Topics: Adult; Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bipolar Disorder; Cyclohexanols; Depressive Disorder, Major; Female; Fluvoxamine; Humans; Male; Middle Aged; Paroxetine; Personality Inventory; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride	2007
An abbreviated version of the Connor-Davidson Resilience Scale (CD-RISC), the CD-RISC2: psychometric properties and applications in psychopharmacological trials. Psychiatry research, 2007, Aug-30, Volume: 152, Issue:2-3 Topics: Antidepressive Agents; Anxiety Disorders; Clinical Trials as Topic; Cyclohexanols; Depressive Disorder, Major; Fluoxetine; Humans; Kava; Mianserin; Mirtazapine; Paroxetine; Psychometrics; Sertraline; Stress Disorders, Post-Traumatic; Surveys and Questionnaires; Venlafaxine Hydrochloride	2007
Severe serotonin toxicity and manic switch induced by combined use of tramadol and paroxetine. The Australian and New Zealand journal of psychiatry, 2007, Volume: 41, Issue:2 Topics: Analgesics, Opioid; Bipolar Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Middle Aged; Pain; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Tramadol	2007
Open trials in psychiatry: comments on article by Uchida et Al. Journal of clinical psychopharmacology, 2007, Volume: 27, Issue:3 Topics: Antidepressive Agents; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Paroxetine; Sulpiride	2007
Simple options for improving signal detection in antidepressant clinical trials. Psychopharmacology bulletin, 2007, Volume: 40, Issue:2 Topics: Antidepressive Agents; Citalopram; Clinical Trials as Topic; Databases, Factual; Depressive Disorder, Major; Dose-Response Relationship, Drug; Double-Blind Method; Duloxetine Hydrochloride; Fluoxetine; Likelihood Functions; Models, Statistical; Paroxetine; Personality Inventory; Placebo Effect; Psychometrics; Reproducibility of Results; Research Design; Signal Detection, Psychological; Thiophenes; Treatment Outcome	2007
Recovery from major depression in older adults receiving augmentation of antidepressant pharmacotherapy. The American journal of psychiatry, 2007, Volume: 164, Issue:6 Topics: Age Factors; Aged; Antidepressive Agents; Bupropion; Combined Modality Therapy; Depressive Disorder, Major; Drug Therapy, Combination; Female; Geriatric Assessment; Humans; Lithium Compounds; Male; Nortriptyline; Paroxetine; Psychotherapy; Secondary Prevention; Time Factors; Treatment Outcome	2007
Benefits and harms of pediatric antidepressant medications. JAMA, 2007, Aug-08, Volume: 298, Issue:6 Topics: Adolescent; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major; Fluoxetine; Humans; Paroxetine; Risk; Selective Serotonin Reuptake Inhibitors	2007
Association study of paroxetine therapeutic response with SERT gene polymorphisms in patients with major depressive disorder. The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry, 2008, Volume: 9, Issue:3 Topics: Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; DNA Primers; Female; Humans; Male; Middle Aged; Minisatellite Repeats; Paroxetine; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins	2008
Delirium associated with paroxetine in an elderly depressive patient: a case report. Pharmacopsychiatry, 2007, Volume: 40, Issue:5 Topics: Aged; Cytochrome P-450 CYP2D6; Delirium; Depressive Disorder, Major; DNA; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors	2007
Reversible paroxetine-induced symptomatic hypothyroidism. Pharmacopsychiatry, 2007, Volume: 40, Issue:5 Topics: Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Hashimoto Disease; Humans; Hypothyroidism; Male; Middle Aged; Paroxetine; Thyroid Hormones	2007
Patient satisfaction with antidepressants: an Internet-based study. Journal of affective disorders, 2008, Volume: 107, Issue:1-3 Topics: Analysis of Variance; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cyclopropanes; Data Collection; Depressive Disorder, Major; Fluvoxamine; Humans; Internet; Japan; Logistic Models; Milnacipran; Paroxetine; Patient Satisfaction; Selective Serotonin Reuptake Inhibitors; Surveys and Questionnaires	2008
ABCB1 (MDR1) gene polymorphisms are associated with the clinical response to paroxetine in patients with major depressive disorder. Progress in neuro-psychopharmacology & biological psychiatry, 2008, Feb-15, Volume: 32, Issue:2 Topics: Adult; Asian People; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Depressive Disorder, Major; Drug Resistance, Multiple; Female; Genes, MDR; Genetic Predisposition to Disease; Genetic Variation; Genotype; Haplotypes; Humans; Male; Middle Aged; Paroxetine; Pharmacogenetics; Polymorphism, Single Nucleotide; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Sex Factors; Treatment Outcome	2008
Pharmacogenetics in modern psychiatry. Psychiatria Danubina, 2007, Volume: 19, Issue:3 Topics: Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Chromosomes, Human, Pair 17; Depressive Disorder, Major; Exons; Genotype; Haplotypes; Humans; Paroxetine; Pharmacogenetics; Phenotype; Polymorphism, Genetic; Prognosis; Promoter Regions, Genetic; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome	2007
A comparison of antidepressant use in Nova Scotia, Canada and Australia. Pharmacoepidemiology and drug safety, 2008, Volume: 17, Issue:7 Topics: Aged; Antidepressive Agents; Australia; Canada; Databases, Factual; Depressive Disorder, Major; Female; Humans; Male; Nova Scotia; Paroxetine; Practice Patterns, Physicians'; Prevalence; Selective Serotonin Reuptake Inhibitors; Sertraline	2008
Sensitivity of the individual items of the Hamilton depression rating scale to response and its consequences for the assessment of efficacy. Journal of psychiatric research, 2008, Volume: 42, Issue:12 Topics: Depressive Disorder, Major; Double-Blind Method; Endpoint Determination; False Negative Reactions; Humans; Linear Models; Longitudinal Studies; Paroxetine; Placebos; Psychiatric Status Rating Scales; Psychometrics; Psychomotor Agitation; Randomized Controlled Trials as Topic; Research Design; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sleep Initiation and Maintenance Disorders; Suicide; Time Factors; Treatment Outcome	2008
The effect of lamotrigine on platelet serotonin concentration in patients with bipolar depression. Psychopharmacology, 2008, Volume: 197, Issue:4 Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bipolar Disorder; Blood Platelets; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Lamotrigine; Lithium Compounds; Middle Aged; Paroxetine; Prospective Studies; Psychiatric Status Rating Scales; Serotonin; Triazines	2008
Antidepressant response and intolerance to SSRI is not influenced by G-protein beta3 subunit gene C825T polymorphism in Japanese major depressive patients. Progress in neuro-psychopharmacology & biological psychiatry, 2008, May-15, Volume: 32, Issue:4 Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Fluvoxamine; Genotype; Heterotrimeric GTP-Binding Proteins; Humans; Japan; Male; Middle Aged; Paroxetine; Polymorphism, Genetic; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors	2008
Serotonin transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. Journal of psychiatry & neuroscience : JPN, 2008, Volume: 33, Issue:2 Topics: Aged; Alleles; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Female; Genotype; Humans; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome	2008
Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy. The American journal of psychiatry, 2008, Volume: 165, Issue:6 Topics: Abnormalities, Drug-Induced; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Heart Defects, Congenital; Humans; Infant; Infant, Newborn; Odds Ratio; Paroxetine; Pregnancy; Pregnancy Complications; Pregnancy Trimester, First; Risk Assessment	2008
Model-based approach and signal detection theory to evaluate the performance of recruitment centers in clinical trials with antidepressant drugs. Clinical pharmacology and therapeutics, 2008, Volume: 84, Issue:3 Topics: Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Depressive Disorder, Major; Double-Blind Method; Humans; Logistic Models; Multicenter Studies as Topic; Paroxetine; Patient Selection; Signal Detection, Psychological; Treatment Outcome	2008
Activation syndrome caused by paroxetine in a cancer patient. Palliative & supportive care, 2008, Volume: 6, Issue:2 Topics: Akathisia, Drug-Induced; Depressive Disorder, Major; Humans; Male; Middle Aged; Pancreatic Neoplasms; Paroxetine; Selective Serotonin Reuptake Inhibitors; Self-Injurious Behavior; Syndrome	2008
Cognitive predictors of treatment response to bupropion and cognitive effects of bupropion in patients with major depressive disorder. Psychiatry research, 2008, Jul-15, Volume: 160, Issue:1 Topics: Adult; Antidepressive Agents, Second-Generation; Brief Psychiatric Rating Scale; Bupropion; Cognition Disorders; Delayed-Action Preparations; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Neuropsychological Tests; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Severity of Illness Index; Treatment Outcome	2008
Placebo as good as paroxetine for treating acute moderate-to-severe major depression. Medscape journal of medicine, 2008, Apr-03, Volume: 10, Issue:4 Topics: Acute Disease; Clinical Trials as Topic; Depressive Disorder, Major; Humans; Paroxetine; Placebo Effect; Treatment Outcome	2008
Increased platelet 5-HT2 receptor binding after electroconvulsive therapy in depression. The journal of ECT, 1998, Volume: 14, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Blood Platelets; Carrier Proteins; Depressive Disorder, Major; Electroconvulsive Therapy; Female; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Radioligand Assay; Receptors, Serotonin; Selective Serotonin Reuptake Inhibitors; Serotonin; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome	1998
Elevation of nortriptyline plasma levels after cotreatment with paroxetine and thioridazine. Journal of clinical psychopharmacology, 1998, Volume: 18, Issue:4 Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Male; Nortriptyline; Paroxetine; Psychiatric Status Rating Scales; Thioridazine	1998
Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Grupo de Trastornos Afectivos. Biological psychiatry, 1999, Aug-15, Volume: 46, Issue:4 Topics: Adolescent; Aged; Antidepressive Agents, Second-Generation; Blood Platelets; Depressive Disorder, Major; Female; Humans; Male; Paroxetine; Predictive Value of Tests; Prognosis; Prospective Studies; Remission Induction; Selective Serotonin Reuptake Inhibitors; Serotonin; Spain; Time Factors	1999
Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT. Psychiatry research, 1999, Apr-26, Volume: 90, Issue:2 Topics: Adult; Aged; Anti-Anxiety Agents; Benzamides; Benzodiazepines; Case-Control Studies; Contrast Media; Corpus Striatum; Depressive Disorder, Major; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Paroxetine; Pyrrolidines; Receptors, Dopamine D2; Selective Serotonin Reuptake Inhibitors; Tomography, Emission-Computed, Single-Photon	1999
Brain metabolic changes in major depressive disorder from pre- to post-treatment with paroxetine. Psychiatry research, 1999, Oct-11, Volume: 91, Issue:3 Topics: Adult; Antidepressive Agents, Second-Generation; Blood Glucose; Brain Mapping; Depressive Disorder, Major; Dose-Response Relationship, Drug; Energy Metabolism; Female; Fluorodeoxyglucose F18; Gyrus Cinguli; Humans; Male; Middle Aged; Paroxetine; Prefrontal Cortex; Prognosis; Tomography, Emission-Computed; Treatment Outcome	1999
Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:1 Topics: Adult; Analysis of Variance; Carrier Proteins; Depressive Disorder, Major; Female; Genotype; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Polymorphism, Genetic; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins; Single-Blind Method	2000
Platelet paroxetine binding in post-traumatic stress disorder. Psychiatry research, 1998, Jan-16, Volume: 77, Issue:1 Topics: Adult; Blood Platelets; Carrier Proteins; Combat Disorders; Depressive Disorder, Major; Humans; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Receptors, Drug; Reference Values; Seasons; Selective Serotonin Reuptake Inhibitors; Serotonin Plasma Membrane Transport Proteins	1998
Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depression and anxiety, 2000, Volume: 11, Issue:2 Topics: Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluoxetine; Humans; Infant, Newborn; Paroxetine; Pregnancy; Pregnancy Complications; Selective Serotonin Reuptake Inhibitors; Sertraline; Treatment Outcome	2000
Simultaneous determination of human plasma levels of four selective serotonin reuptake inhibitors by high-performance liquid chromatography. Therapeutic drug monitoring, 2000, Volume: 22, Issue:3 Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Chromatography, High Pressure Liquid; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Interactions; Drug Therapy, Combination; Female; Fluorometry; Fluoxetine; Fluvoxamine; Humans; Linear Models; Male; Middle Aged; Paroxetine; Selective Serotonin Reuptake Inhibitors; Sensitivity and Specificity; Sertraline	2000
Effect of paroxetine on thyroid hormone levels in severely depressed patients. Neuropsychobiology, 2000, Volume: 42, Issue:3 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Suicide; Suicide Prevention; Thyroid Hormones; Thyrotropin-Releasing Hormone; Thyroxine	2000
The clinical response to total sleep deprivation and recovery sleep in geriatric depression: potential indicators of antidepressant treatment outcome. Psychiatry research, 2000, Dec-04, Volume: 97, Issue:1 Topics: Aged; Aging; Antidepressive Agents, Second-Generation; Combined Modality Therapy; Depression; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Male; Middle Aged; Paroxetine; Predictive Value of Tests; Psychiatric Status Rating Scales; Selective Serotonin Reuptake Inhibitors; Sleep Deprivation; Treatment Outcome	2000
A case of paroxetine-induced dyskinetic movements. Journal of clinical psychopharmacology, 2000, Volume: 20, Issue:6 Topics: Aged; Depressive Disorder, Major; Dyskinesia, Drug-Induced; Female; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors	2000
Effect of paroxetine on plasma vasopressin and water load testing in elderly individuals. Journal of geriatric psychiatry and neurology, 2000,Winter, Volume: 13, Issue:4 Topics: Aged; Arginine Vasopressin; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Paroxetine; Water-Electrolyte Balance	2000
Re: Managing depression refractory to SSRIs. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2000, Volume: 45, Issue:9 Topics: Adult; Bupropion; Depressive Disorder, Major; Drug Therapy, Combination; Female; Humans; Paroxetine; Treatment Outcome	2000
Galactorrhea induced by paroxetine. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2001, Volume: 46, Issue:1 Topics: Adult; Depressive Disorder, Major; Female; Galactorrhea; Humans; Paroxetine; Prolactin	2001
Prefrontal changes and treatment response prediction in depression. Seminars in clinical neuropsychiatry, 2001, Volume: 6, Issue:2 Topics: Adult; Antidepressive Agents; Cyclohexanols; Depression; Depressive Disorder, Major; Electroencephalography; Female; Fluoxetine; Humans; Male; Middle Aged; Paroxetine; Prefrontal Cortex; Sertraline; Venlafaxine Hydrochloride	2001
Improvement of acne in depressed patients treated with paroxetine. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, Volume: 40, Issue:5 Topics: Acne Vulgaris; Adolescent; Adult; Antidepressive Agents; Depressive Disorder, Major; Female; Humans; Male; Paroxetine; Severity of Illness Index; Treatment Outcome	2001
Mood disorders in children and adolescents: psychopharmacological treatment. Biological psychiatry, 2001, Jun-15, Volume: 49, Issue:12 Topics: Adolescent; Antidepressive Agents, Tricyclic; Child; Depressive Disorder, Major; Drug Therapy, Combination; Fluoxetine; Health Services Needs and Demand; Humans; Imipramine; Mood Disorders; Paroxetine; Selective Serotonin Reuptake Inhibitors	2001
Brain metabolic changes associated with symptom factor improvement in major depressive disorder. Biological psychiatry, 2001, Aug-01, Volume: 50, Issue:3 Topics: Depressive Disorder, Major; Fluorodeoxyglucose F18; Gyrus Cinguli; Humans; Paroxetine; Prefrontal Cortex; Psychomotor Disorders; Psychotherapy; Radiopharmaceuticals; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Tomography, Emission-Computed	2001
[Paroxetine augmentation with risperidone in therapy-resistant depression]. Psychiatrische Praxis, 2001, Volume: 28, Issue:8 Topics: Aged; Depressive Disorder, Major; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Paroxetine; Recurrence; Risperidone; Treatment Outcome	2001
No association between dopamine D(2) and D(4) receptor gene variants and antidepressant activity of two selective serotonin reuptake inhibitors. Psychiatry research, 2001, Nov-30, Volume: 104, Issue:3 Topics: Depressive Disorder, Major; Exons; Female; Fluvoxamine; Gene Expression; Gene Frequency; Humans; Male; Middle Aged; Paroxetine; Receptors, Dopamine D2; Receptors, Dopamine D4; Selective Serotonin Reuptake Inhibitors	2001
Effects of long-term lithium treatment on monoaminergic functions in major depression. Psychiatry research, 2001, Dec-15, Volume: 105, Issue:1-2 Topics: Adult; Aged; Bipolar Disorder; Blood Platelets; Carrier Proteins; Depressive Disorder, Major; Female; Humans; Lithium Carbonate; Lysergic Acid Diethylamide; Male; Membrane Glycoproteins; Membrane Transport Proteins; Middle Aged; Nerve Tissue Proteins; Paroxetine; Radioligand Assay; Receptors, Adrenergic, alpha-2; Receptors, Serotonin; Serotonin; Serotonin Plasma Membrane Transport Proteins; Treatment Outcome	2001
SSRIs associated with behavioral activation and suicidal ideation. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, Volume: 40, Issue:12 Topics: Attention Deficit and Disruptive Behavior Disorders; Child; Depressive Disorder, Major; Fluvoxamine; Humans; Male; Paroxetine; Suicide, Attempted	2001
Differential cerebral metabolic changes with paroxetine treatment of obsessive-compulsive disorder vs major depression. Archives of general psychiatry, 2002, Volume: 59, Issue:3 Topics: Adult; Blood Glucose; Brain; Brain Mapping; Comorbidity; Depressive Disorder, Major; Energy Metabolism; Female; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Obsessive-Compulsive Disorder; Paroxetine; Personality Inventory; Radiography; Tomography, Emission-Computed; Treatment Outcome	2002
Antidepressant side effects in depression patients treated in a naturalistic setting: a study of bupropion, moclobemide, paroxetine, sertraline, and venlafaxine. Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2002, Volume: 47, Issue:2 Topics: Adult; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Bupropion; Canada; Cyclohexanols; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Moclobemide; Paroxetine; Sertraline; Treatment Outcome; Venlafaxine Hydrochloride	2002
Paroxetine in adolescent major depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, Volume: 41, Issue:4 Topics: Adolescent; Depressive Disorder, Major; Humans; Multicenter Studies as Topic; Paroxetine; Selective Serotonin Reuptake Inhibitors	2002
Paroxetine in adolescent major depression. Journal of the American Academy of Child and Adolescent Psychiatry, 2002, Volume: 41, Issue:4 Topics: Adolescent; Depressive Disorder, Major; Humans; Paroxetine; Selective Serotonin Reuptake Inhibitors	2002
EEG correlates of acute and chronic paroxetine treatment in depression. Journal of affective disorders, 2002, Volume: 69, Issue:1-3 Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder, Major; Electroencephalography; Humans; Male; Paroxetine; Psychiatric Status Rating Scales	2002